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Abstract 
The antitumor ether lipid ET-18-OCH3 (edelfosine) is the prototype of a new class of 
antineoplastic agents, synthetic analogues of lysophosphatidylcholine, that shows a high 
metabolic stability, does not interact with DNA and shows a selective apoptotic response in 
tumor cells, sparing normal cells. Unlike currently used antitumor drugs, ET-18-OCH3 does not 
act directly on the formation and function of the replication machinery, and thereby its effects 
are independent of the proliferative state of target cells. Because of its capacity to modulate 
cellular regulatory and signaling events, including those failing in cancer cells, like defective 
apoptosis, ET-18-OCH3, beyond its putative clinical importance, is an interesting model 
compound for the development of more selective drugs for cancer therapy. Although ET-18-
OCH3 enhances host defense mechanisms against tumors, its major antitumor action lies in a 
direct effect on cancer cells, inhibiting phosphatidylcholine biosynthesis and inducing apoptosis 
in tumor cells. Recent progress has allowed unraveling the molecular mechanism underlying the 
apoptotic action of ET-18-OCH3, leading to the notion that ET-18-OCH3 is selectively 
incorporated into tumor cells and induces cell death by intracellular activation of the cell death 
receptor Fas/CD95. This intracellular Fas/CD95 activation is a novel mechanism of action for an 
antitumor drug and represents a new way to target tumor cells in cancer chemotherapy that can 
be of interest as a new framework in designing novel antitumor drugs. ET-18-OCH3 and some 
analogues are pleiotropic agents that affect additional biomedical important diseases, including 
parasitic and autoimmune diseases, suggesting new therapeutic indications for these compounds. 
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1. Introduction 
Synthetic ether-linked analogues of lysophospholipids were synthesized in the late 60s as 
metabolically stable analogues of lysophosphocholine, and constitute a new class of antitumor 
drugs that do not directly target DNA, but seem to target the cell membrane. These synthetic 
lipid molecules were the first antineoplastic agents that did not act directly on the formation and 
function of the cellular replication machinery, and therefore their effects were independent of the 
proliferative state of the target cells. In the last three decades a wealth of knowledge on their 
properties and actions has been accumulated. A number of excellent reviews have appeared 
concerning the antitumor activities and biochemical processes affected by these synthetic ether-
linked analogues of lysophospholipids and by synthetic alkylphosphocholines, collectively 
known as antitumor lipids (ATLs) [1-8]. However, some of the actions assigned to these lipid 
molecules can be questioned as they are evidenced at drug concentrations much higher than 
those required for achieving their antitumor effects. This is of particular importance when 
dealing with lipidic drugs, as lipids are prone to promote nonspecific events, especially when 
used at high concentrations that can prevent or divert attention from the specific and relevant 
actions. Conflicting and contradictory observations among different groups, using a wide 
diversity of drug concentrations and cell types, together with an increasing number of reports 
suggesting the participation of ATLs in a wide array of physiological processes as well as the 
involvement of different signaling processes in the mechanism of action of ATLs, have led to a 
certain confusion to discern the main biological effects exerted by these drugs and the underlying 
primary signaling routes from secondary and irrelevant events. A pivotal development in 
understanding the mechanism of action of ATLs was the demonstration in 1993 that these lipids 
induced apoptosis in target cells [9,10], and this key finding accounts for the cytotoxic activity of 
the ether lipids. Furthermore, we have recently found that ET-18-OCH3 (edelfosine), considered 
as the major prototype of ATLs, induces selectively apoptosis in tumor cells, sparing normal 
cells, and that this lipid drug triggers directly the apoptotic machinery of tumor cells [11,12], 
unlike other antitumor drugs that promote indirectly apoptosis. Accordingly, current 
investigations try to unravel how this apoptotic-directed killing is triggered. Recent evidence 
indicates that ET-18-OCH3 is the first antitumor drug acting through activation of the cell death 
receptor Fas/CD95 [12]. There is now a renewed and growing interest in these ATLs as 
antitumor agents due to their selectivity against tumors that is in part due to their high metabolic 
stability. During the last eight years a number of key findings have been reported that allow to 
lay the foundations to understand and unravel the mechanism of action of these promising 
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antitumor drugs. These novel findings indicate that ATLs represent a new type of antitumor 
drugs targeting for the apoptotic machinery and plasma membrane. In addition, a number of 
preclinical data have been reported that seem to bring a putative clinical application closer. The 
present review covers the state of the art in the incorporation, metabolism, and mechanism of 
action of the antitumor drug ET-18-OCH3, which has become the effective and standard 
prototype of ATLs. A major purpose of this review is to emphasize the important effect of ET-
18-OCH3 in triggering apoptosis in tumor cells through the activation of the apoptotic machinery 
that was dormant in cancer cells, as well as to discuss the need for searching new proapoptotic 
drugs in the treatment of cancer. This review also summarizes the preclinical and clinical 
experience obtained to date with this drug on cancer treatment and on new putative additional 
biomedical indications that can also be of major importance in near future. 
 
2. Two major types of antitumor lipids 
Synthetic antitumor lipids (ATLs) can be classified into two major categories (Fig. (1)): 
a) the alkyl ether phospholipids (AEPs), widely referred to collectively as antitumor ether lipids 
(AELs) or alkyl-lysophospholipid analogues (ALPs), containing ether bonds in the glycerol 
backbone of the phospholipid, as exemplified by 1-O-octadecyl-2-O-methoxy-rac-glycero-3-
phosphocholine (ET-18-OCH3; edelfosine); b) and the alkylphosphocholines (APCs), lacking the 
glycerol backbone and formed by a simple long-chain alcohol esterified to a phosphobase, as 
exemplified by hexadecylphosphocholine (HPC; miltefosine). All of these ATLs are 
distinguished by their low rates of metabolism in vitro and in vivo. AEPs and APCs share a 
number of biological actions, but they seem to act differently. Furthermore, new classes of 
synthetic ATLs are being synthesized with promising antitumor activities, including: a) sugar-
containing analogues of lysophosphatidylcholine [13-17]; b) phosphonate-derived ether lipids 
[18,19]; c) plasmenyl analogues of ET-18-OCH3 [20,21]; d) new analogues of HPC, such as 
erucylphosphocholine [22,23] and perifosine [24,25]; e) phosphocholine-containing analogues of 
sphingomyelin [26]; f) alkylphosphonophosphate analogues of 1-β-D-arabinofuranosylcytosine 
(ara-C), such as cytoros [27]. The present review focuses on the current knowledge and new 
insights about the uptake, metabolism, mechanism of action and biomedical activities of ET-18-
OCH3, as the prototype of AEPs, that can be extended to other ATLs. 
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3. Cancer chemotherapy and apoptosis 
There is a need to overcome the dead-lock in the present chemotherapeutical state of 
cancer treatment with further developments of new chemotherapeutic drugs different from the 
classical compounds used in clinical practice. The era of chemotherapy was ushered in by the 
introduction of polyfunctional alkylating agents in the early 1940’s. Since then, a wide array of 
antitumor drugs has become available. Most of the chemotherapeutic agents used in clinic exert 
their major antitumor effects by affecting either DNA itself, DNA synthesis or cell division, thus 
inhibiting cells that undergo proliferation. However, the results obtained from the use of these 
drugs have been rather poor. An undesirable consequence of these drugs actions is that those 
normal tissues that have a high rate of cellular proliferation bear the brunt of toxic side effects, 
leading to a number of clinical manifestations of toxicity. These normal tissues include the 
normal bone marrow (leading to anemia, leukopenia –infection-, thrombocytopenia –bleeding-), 
the gastrointestinal epithelial cells (diarrhea, vomiting, nausea, surface ulcerations), and the cells 
of the hair follicles (alopecia).  
In this regard, the lack of selectivity of the current antitumor agents is a major problem in 
cancer chemotherapy, and leads to compounds with a rather poor therapeutic index, defined as 
the ratio of maximum tolerated dose/minimum effective dose. Medically useful drugs should 
ideally have a high therapeutic index. The only modest progress in cancer chemotherapy over the 
past sixty years suggests that some of the frameworks used for targeting the cancer cell are 
wrong. Perception of the malignant cell as having only an uncontrolled proliferation is one of 
such frameworks. The rather modest impact of antiproliferative drugs in clinic is not surprising 
since many tumors have a low growth capacity. In contrast, increasing evidence is leading to the 
conception of a tumor cell as a cell mainly defective in triggering its own death by apoptosis. In 
this way of thinking, a common feature in the tumor cell would be a blockade or deficiency in its 
capacity to trigger its own cell death by apoptosis. This defective apoptosis could be even a more 
relevant and general feature than an unregulated proliferation in the process of tumorigenesis. 
It was previously considered that drug- or radiation-induced damage, like DNA strand 
breaks, were directly responsible for the death of the cell, leading to a metabolic catastrophe. 
However, it is now assumed that cells sense this damage and react according to their phenotype 
[28], that is to say cells respond to a drug-induced perturbation of cellular metabolism. Cells 
sense alterations or damages in the cell metabolism or in the distinct biochemical processes 
required for the normal life of the cell or in the genome through the presence of “sensors”, 
calibrate these lesions and mount a response to these aggressions. When this metabolic, 
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biochemical or DNA damage is excessive or difficult to be repaired, the cell decides to self-
destruct altruistically by apoptosis avoiding in this way to threaten the health of neighbor cells 
and tissues. The failure of some tumor cells to die following a chemotherapeutic treatment may 
be due to their resistance to engage apoptosis. This implies the existence of a molecular 
threshold for the engagement of cell death, that we coin as “apoptosis threshold”, in response to 
damage that is set differently in distinct cell types (Fig. (2)). Differences in apoptosis thresholds 
between different cell types may reflect differences in the expression or sensitivity of cellular 
sensors or in down-stream events set in motion by the sensors. Tumor cells may either inhibit the 
molecular processes that lead to their own death, and/or increase remarkably the apoptosis 
threshold required to realize that they are receiving a signal driving them to commit suicide. 
There are big differences among different cell types concerning the capacity to invoke a response 
after damage, some cells may die readily and others may be very resistant. Most of the human 
cancers (about 86% of all cancer types) derive from epithelial cells (carcinoma). This suggests 
that epithelial tissue has a high apoptosis threshold, that is it tolerates a high number of external 
insults or damage before mounting an apoptotic response, and thereby this tissue might show a 
higher predisposition to accumulate mutations leading ultimately to cancer. The high apoptotic 
threshold of epithelium can be due to the fact that is exposed to environmental threats and 
therefore should be more permissible to risk some damage in order to avoid a high cell death 
rate. In contrast, the bone marrow, that is protected from external insults, would show a lower 
threshold for the engagement of cell death and this might explain why hematopoietic and 
immune system tumors are relatively much less frequent (about 8% of all cancer types). This low 
apoptotic threshold also explains the deleterious effects and the ease of chemotherapy- and 
radiation-induced cell death in the bone marrow. 
Carcinogenesis is a multistage process which involves damage to the genome, 
accumulating mutations in specific genes. This leads to the modification of either the activity or 
the amount of protein products coded by those genes, perturbing in this way the normal cell 
function. These changes, promoted originally by a genomic damage, are detected by cellular 
sensors, which, in turn, set several signaling mechanisms leading to a rapid apoptotic cell death 
in those cells with a low or normal apoptotic threshold (Fig. (1)). In this way, the timely 
induction of apoptosis would prevent tumor development. However, cancer cells try to survive at 
any cost, and thereby inhibit or get rid of sensors and apoptotic signaling (Fig. (3)), either 
modifying their expression levels or function, that otherwise could lead to their own cell death. 
Thus, a tumor cell shows (Fig. (3)): a) inhibition of sensors promoting apoptosis; b) inhibition or 
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blockade of apoptosis signaling; c) potentiation of survival signaling. These effects lead to an 
abnormally high apoptosis threshold in tumor cells (Figs. (2) and (3)). Impaired apoptosis 
signaling is common in cancer cells and may play an important role in tumor initiation, 
progression and metastasis, as apoptosis normally eliminates cells with genomic damage or 
deregulated cell cycle, and apoptosis-deficient tumor cells are able to accumulate mutations, 
survive the transit in the bloodstream and grow in ectopic tissues. The ability to metastasize 
makes cancers hard to eradicate surgically or by localized irradiation and leads to the high death 
rate on cancer patients. During metastasis, cancer cells originally located in a specific tissue: a) 
loose their adhesion to neighboring cells in the original tissue by decreasing the expression of 
adhesion molecules; b) escape from the tissue of origin and burrow through tissues, through 
generation of proteolytic enzymes that can break down extracellular matrix, until they reach a 
blood vessel or a lymphatic vessel; c) enter the bloodstream by crossing the basal lamina and 
endothelial lining of the blood vessel wall or by crossing the wall of a lymphatic vessel that 
ultimately discharges its contents into the bloodstream; d) adhere to capillary walls in other 
tissues, extravasate and proliferate in the new environment to form metastasis at a new homing 
tissue, or become trapped in lymph nodes, giving rise to lymph-node metastasis. Only a tiny 
proportion (less than 0.1%) of the cells released into circulation by tumors survive and succeed 
in founding metastatic colonies. A higher apoptosis threshold in cancer cells results in a higher 
survival capacity in adverse conditions and therefore, in a higher ability to metastasize, as well as 
in a higher resistance against therapy. Thus, resistance of cancer cells to apoptosis is especially 
deleterious because it enhances the malignant potential of the tumor, favoring accumulation of 
mutations, metastasis and rendering tumor cells resistant to therapy as well as to host defense 
mechanisms. 
The idea of developing drugs able to induce apoptosis in tumor cells constitutes an 
attractive and promising approach in cancer treatment. This induction of apoptosis can be 
rendered through: a) direct activation of the apoptotic machinery in the tumor cell; b) induction 
of certain damages that can be sensed by the tumor cell to engage its own cell death; c) re-
establishing or setting the capacity to undergo apoptosis following an external insult or genomic 
damage; d) inhibiting survival signaling in the cancer cell. 
 Very recent evidence indicates that the antitumor ether lipid ET-18-OCH3 constitutes the 
first drug that directly activates the apoptotic signaling of tumor cells [11,12], and thereby it can 
constitute the leading compound of a new class of synthetic drugs targeting apoptotic machinery. 
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4. History 
In the early 1960s Herbert Fischer and Paul Gerhard Munder working at the Max-Planck-
Institut für Immunbiologie in Freiburg (Germany) on the role of macrophage activation in 
silicosis found that during phagocytosis of silicogenic quartz particles, phospholipase A2 was 
activated, leading to the generation of lysolecithin (2-lysophosphatidylcholine, LPC) and its 
accumulation in the macrophage cell membrane. They suggested that LPC could play a role in 
macrophage activation and, indeed, they found that immune adjuvants induced phospholipase A2 
activation in macrophages [29,30], and small amounts of exogenous LPC strongly enhanced the 
phagocytic activity of peritoneal macrophages in vitro and in vivo. These results suggested that 
LPC could play a role in the defense mechanisms of the immune system, and prompted these 
authors to further study the role of LPC in the immune response. However, the naturally 
occurring LPC behaves as a highly active detergent [31], and thereby has a short half-life time, 
being biologically inactivated either by retransformation into lecithin (phosphatidylcholine, PC) 
through the action of acyltransferase, or by metabolization to glycerophosphocholine through the 
action of lysophospholipase [32] (Fig. (4)). Then, LPC analogues with longer half-life times in 
vivo were synthesized in the following years following a join effort of different groups led by 
Herbert Fisher, Otto Westphal, Hans Ulrich Weltzien and Paul Gerhard Munder in Freiburg 
[2,4]. Particular emphasis was made on changes in the positions C1 and C2 of the glycerol 
backbone in the molecule of LPC (1-acyl-sn-glycero-3-phosphocholine), replacing ester bonds 
for ether linkages in order to render analogues unable to be metabolized for either 
acyltransferases or lysophospholipases. Thus, some of the major changes included: i) the sn-1 
ester acyl-bond was replaced by an ether alkyl-bond, with an aliphatic side chain length of 10-22 
carbon atoms, which cannot be affected by lysophospholipase activity and only can be split 
apparently by an 1-O-alkyl-cleavage enzyme [33]; ii) The OH group in sn-2 of the molecule was 
transformed into a short-chain ether, such as a methoxi (OCH3) group, preventing the acylation 
of the lysophospholipid to PC. As expected, some of these synthesized ether analogues of LPC 
turned out to be potent immune modulators [34], but surprisingly Munder and co-workers found, 
in the course of these studies, that some these ether lipids exerted strong antitumor activities in 
vitro and in vivo [35,36]. Munder and Westphal, using a large variety of synthetic analogues of 
lysolecithins, with longer half-life times in vivo, demonstrated that several of these lipid 
compounds selectively destroyed tumor cells [36-39]. Among the synthesized lysolecithin ether 
lipid analogues, 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-18-OCH3, 
edelfosine) turned out to be the most effective antitumoral compound, and rapidly became the 
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effective standard in trials on antitumoral activities of such ether lipids [2]. The first synthesis of 
ET-18-OCH3 was described by Guenter Kny in 1969 [40], a chemical diploma student in O. 
Westphal’s laboratory, making use of the previous experience of Bernd Arnold and Hans Ulrich 
Weltzien with the synthesis of 1-O-alkyl- and 2-O-methyl derivatives of glycerol. Among the 
more potentially useful compounds which were subjected to clinical trials were edelfosine (1-O-
octadecyl-2-O-methyl-rac-glycero-3-phosphocholine) and ilmofosine (1-S-hexadecyl-2-
methoxymethyl-2-desoxy-rac-glycero-3-phosphocholine, BM 41.440).  
 
5. Natural glycerol ethers 
A very close structurally related compound with ET-18-OCH3 is platelet-activating factor 
(PAF) that plays an important role in inflammation [41-43]. The natural product PAF was 
identified in 1979-1980 as a 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine [44,45], in which 
the alkyl group is mainly a C16 and C18 aliphatic chain, that is a decade after the synthesis of 
ET-18-OCH3. Therefore, only by chance ET-18-OCH3 can be considered as a 2-O-methyl 
synthetic analogue of PAF. Nevertheless, PAF has no antitumor activity in vitro or in vivo, and 
ET-18-OCH3 does not exert significant PAF or anti-PAF activity in vivo. 
Long-chain alkyl and alkenyl ethers of glycerol are known to occur in nature and are 
present in various animal tissues, including intestinal fat, liver, spleen, the domestic hen 
(particularly in the egg yolk), bone marrow and milk of cattle and man, erythrocytes [46]. Two 
main functions of natural glyceryl ethers have been suggested, namely as membrane components 
[47] and as mediators of cell responses [48]. The first indications of a naturally occurring 
glyceryl ether lipid of a long-chain fatty alcohol were obtained by Dorée in 1909 and Kossel and 
Edlbacher in 1915 in the alcohol fractions obtained from starfishes Asterias rubens and 
Astrospecten aurantiacus, respectively [49]. This alcohol was later shown to be batyl alcohol (3-
1’-octadecyloxypropane-1,2-diol or 1-O-stearyl glyceryl ether) [49]. Then, a series of 1-glyceryl 
ethers in the nonsaponifiable fractions of liver oils of Elasmobranchs were found by Tsujimoto 
and Toyama in the early and mid 1920s, which were named batyl alcohol, chimyl alcohol (3-1’-
hexadecyloxypropane-1,2-diol or 1-O-palmityl glyceryl ether) and selachyl alcohol (3-1’-
octadec-9’-enyloxypropane-1,2-diol or 1-O-oleyl glyceryl ether), after the respective fish source, 
sea rays (Batoidei), ratfish (Chimera) and sharks  (Selachoidei) [46,50]. These glyceryl ethers 
were also found in some marine sponges, including Stylopus australis, Tethya aurantia, Tedania 
ignis, Ulosa Ruetzleri, Desmapsamma anchorata [50]. It has been reported that these marine 
glyceryl ethers have some medicinal activities, such as an acceleration effect on blood cell 
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formation in the marrow, a bacteriostatic effect, an anti-inflammatory effect, and an antitumor 
activity [46,51-56]. Different structures of glyceryl ethers, including terpene glyceryl ethers and 
macrocyclic ether lipids have been also found in microorganisms, such as the extreme halophile 
Halobacterium cutirubrum and archaebacteria, which exhibit unusual resistance to adverse 
environmental conditions [57,58]. Fecapentaenes, polyunsaturated glyceryl ethers [59] produced 
by Bacteroides species present in the lumen of the human colon and present in the feces, have 
been suggested to be mutagens and colon carcinogens [60,61]. 
Ether-linked species are also important contributors to both choline and ethanolamine 
glycerophospholipids in mammalian tissues. In most tissues, the predominant ether-linked 
choline phospholipid species is plasmanylcholine (1-O-alkyl-2-acyl-sn-glycero-3-
phosphocholine) while plasmenylethanolamine (1-O-alk-1’-enyl-2-acyl-sn-glycero-3-
phosphoethanolamine) is the primary ether-linked ethanolamine phospholipid species. A notable 
exception to this is heart from several species (except rat) and bovine spermatozoa in which 33-
52% and about 63% of the PC, respectively, is in the plasmenyl form [62,63]. High levels of 
alkyl and alk-1-enyl moieties in both choline and ethanolamine glycerophospholipids occur in 
human neutrophils [64]. Those glycerophospholipids with alk-1-enyl (plasmenyl or vinyl ether, 
that is a cis double bond adjacent to the ether linkage) groups at the sn-1 position of the glycerol 
backbone are referred to as plasmalogens (i.e. choline plasmalogens and ethanolamine 
plasmalogens). To date, the physiological role of plasmalogens is not clear, although various 
important functions have been suggested, such as modulation of membrane fluidity and phase 
transition temperature [65], protection against oxidative stress [66], participation in signal 
transduction processes [48,67], and facilitation of membrane fusion [68] and membrane 
trafficking [69]. It has also been suggested that plasmalogens function as a reservoir for 
polyunsaturated fatty acids [70,71] which, when  released by a calcium-independent, 
plasmalogen-specific phospholipase A2 (PLA2) [72-74], form bioactive molecules, such as 
prostaglandins and leukotrienes. In this regard, plasmenylethanolamines are a major storage 
depot for arachidonic acid [75,76]. Moreover, the lysoplasmalogens generated from 
ethanolamine plasmalogens via PLA2 hydrolysis can induce the biosynthesis of the potent lipid 
mediator PAF, through CoA-independent transacylases [77-80]. 
Interestingly, plasmenylcholine analogues of the antitumor ether lipid ET-18-OCH3, 
incorporating a cis-O-vinyl linkage into the sn-1 position of the glycerol backbone, have been 
synthesized very recently and show an antiproliferative effect in tumor cell lines in vitro [20,21].  
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6. Cellular uptake 
There is a strong correlation between the cellular uptake of ET-18-OCH3 and the 
cytotoxic ability of the drug [11,12,81-85]. Unlike tumor cells, normal cells are unable to take up 
significant amounts of the ether lipid [11,12]. We have recently demonstrated by combining 
microinjection and in situ DNA fragmentation assays that incorporation of ET-18-OCH3 into the 
cell is a necessary requirement for ET-18-OCH3-induced apoptosis, and normal cells are spared 
because they are not able to incorporate enough amounts of the ether lipid [12]. Thus, a primary 
culture of normal human fibroblasts did not incorporate significant amounts of [3H]ET-18-OCH3 
even after long-term incubations (more than 72 h) and were resistant to the apoptotic action of 
the ether lipid, but microinjection of the ether lipid into these normal cells prompted rapid 
apoptosis [12]. These data demonstrate that incorporation of ET-18-OCH3 into the cell is a 
crucial event in the selective apoptotic action of the ether lipid on tumor cells. These experiments 
also indicate that the cell membrane acts as a barrier to ET-18-OCH3 in normal cells. 
Furthermore, we found that microinjected ET-18-OCH3 induced apoptosis in a dose-response 
pattern [12], suggesting that a threshold for intracellular ET-18-OCH3 concentration must be 
reached in order to trigger apoptosis. 
The amount of ET-18-OCH3 incorporated into the cell plays an important role in 
determining the cytotoxicity of ET-18-OCH3, and the number of drug molecules per cell is a 
critical determinant of the cytotoxicity of ET-18-OCH3. The cell density may determine the 
“effective” exposure dose in that the drug is diluted among more cells. Therefore, exposure dose 
and cell density are important parameters in determining the killing effect induced by ET-18-
OCH3 [83]. In addition to drug dose and cell density, there are more variables that affect ether 
lipid uptake. Thus, cellular incorporation of ET-18-OCH3 depends on the cell type, percent of 
serum proteins in the assay, temperature, etc.  
Although ether lipid uptake is of pivotal importance for the biological action of ET-18-
OCH3, conflicting data have been reported in order to explain how this ether lipid is 
incorporated. Although no conclusive notion has been reached, direct adsorption onto the plasma 
membrane followed by passive diffusion, endocytosis, lipid flip-flop, and a specific protein-
directed incorporation have been postulated for ET-18-OCH3 uptake. 
AEPs do not directly interact with DNA, but due to their phospholipid nature they are 
readily incorporated into cellular membranes [86-89]. Lysophospholipids have a high monomer 
concentration (e.g., the critical micelle concentration of 1-palmitoyl glycerophosphocholine is 7 
x 10-6 M) and are inserted spontaneously into synthetic bilayers [90,91]. This can be also the 
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mechanism of ET-18-OCH3 membrane association as it is a lysophospholipid analogue. In fact, 
ET-18-OCH3 has been reported to be incorporated into various tumor cell membranes to the 
extent that accounted on for up to 17% of the purified membrane phospholipids of the 
membranes [88]. Three major steps must be considered in the uptake of a lipid: a) association 
with the plasma membrane; b) internalization; and c) metabolism. ET-18-OCH3 is not 
significantly metabolized (see below) and can interact with the plasma membrane of both 
sensitive and resistant cells in a similar non-specific way. Thus, [3H]ET-18-OCH3 bound in 
similar amounts to both resistant and sensitive cells [84] at low temperatures (4ºC) when cellular 
processes, such as membrane internalization or possible protein-facilitated transbilayer 
movement are greatly slowed or stopped, suggesting that ether lipids tend to interact 
unspecifically with membranes. However, when cells were warmed at room temperature to allow 
internalization processes to become active, about 80% of the pre-bound ET-18-OCH3 was 
internalized in sensitive cells, while only 10-20% of pre-bound ether lipid was taken up by 
resistant cells [84]. On these grounds, cellular uptake of this antitumor drug seems to be 
dependent on an internalization process. Internalized lipid (uptake) can be readily evaluated 
through extensive washing of the cells in either serum- or bovine serum albumin (BSA)-
containing medium [92], in order to remove ET-18-OCH3 remaining on the cell surface due to 
the ability of the ether lipid to interact with BSA and serum proteins. Internalized ET-18-OCH3 
is unavailable to BSA and therefore cannot be removed, but loosely membrane bound ether lipid 
can be washed off. This is due to the fact that ET-18-OCH3 has the similar high affinity binding 
to serum albumin as also described for natural LPC [81,93].  
It has been reported that inhibition of endocytosis by a number of agents (chloroquine, 
monensin, vinblastine) inhibited both the cell-killing effect and the uptake of ET-18-OCH3 in 
drug-sensitive leukemic cells [94], suggesting that endocytosis was a major route for ET-18-
OCH3 uptake. However, ET-18-OCH3 uptake by drug-sensitive cell lines has been shown to be 
unaffected by metabolic inhibitors of ATP biosynthesis, suggesting that ET-18-OCH3 uptake did 
not occur via endocytosis, and it did not depend apparently on cellular energy [81]. Although 
most of the uptake studies have been carried out in the presence of 10% fetal calf serum (FCS) in 
the culture medium, that can affect lipid uptake, short time unidirectional ET-18-OCH3 uptake 
studies have been also carried out in serum-free medium in order to avoid the confounding effect 
of binding to serum components. Under these conditions ET-18-OCH3 uptake in L1210 murine 
leukemia cells was found non-saturable and was not affected by the metabolic inhibitors 
choroquine, monensin or cytochalasin B, that are known inhibitors of endocytosis [95]. ET-18-
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OCH3 binds to serum proteins, primarily albumin and high density lipoprotein (HDL). A study 
indicates that the majority of the ether lipid (71%) is bound to albumin and about 6% to HDL 
[96], whereas another study reports that ET-18-OCH3 binds to both albumin and HDL in about 
similar proportions (40%) [95]. Therefore this protein binding reduces the extracellular 
concentration of free drug and the cellular uptake of ET-18-OCH3. In this regard, addition of 
serum to the incubation medium inhibits the cytotoxicity of AEPs in a concentration-dependent 
manner [95,97,98, Gajate, C. and Mollinedo, F., unpublished data], and this is likely related to 
reduced uptake. Addition of human serum or human albumin reduced uptake by approximately 
50% at levels as low as 0.5-1% serum or albumin [93]. Uptake has been reported to be reduced 
at 23ºC as compared to 37ºC, reaching a steady-state level of approximately 50% of the values 
for 37ºC, and the uptake was still lower at 0ºC, reaching a plateau about 50% lower than at 23ºC 
[93]. These data in serum-free medium suggested a non-saturable, energy independent and 
moderately temperature sensitive drug uptake that can be compatible with a passive diffusion 
mechanism [93]. The lipidic nature of ET-18-OCH3 and its rather low molecular weight (mw = 
524) would also agree with a passive diffusion mechanism, as lipophilicity and molecular weight 
are major determinants of diffusion. A plausible mechanism could be that the ether lipid might 
be incorporated directly into the plasma membrane by passive diffusion and then internalized by 
flip-flop to the cytoplasmic face of the bilayer or by other non-energy-dependent mechanisms 
[95,99]. However, because flip-flop is inherently slow and ET-18-OCH3 uptake follows a rapid 
kinetics, the assistance of a transmembrane transporter would be likely required. The putative 
participation of transporters, that play a role in the maintenance or dissipation of transbilayer 
lipid asymmetry, in ET-18-OCH3 uptake remains to be analyzed. These transporters can be 
divided into three classes, based on the direction of transport of the lipid substrate: a) 
“scramblases”, which facilitate the bi-directional movement of lipids across the bilayer; b) 
“flippases”, which catalyze the cytofacially directed transport of lipids; and c) “floppases”, 
which promote the movement of lipids from the cytoplasmic to the external face of the 
membrane [100]. The demonstration that MDR1 and MDR3 P-glycoproteins function as PC 
translocators [101] raises the possibility that lipid transporters can play a role in ET-18-OCH3 
uptake or extrusion. In this regard, it has been reported that the PC analogue ET-18-OCH3 is a 
substrate for class I and class II P-glycoproteins and other ABC transporters, that mediate 
pleiotropic drug resistance in a wide range of organisms [102]. Also, because ET-18-OCH3 binds 
to albumin and HDL in serum, it could also be suggested that albumin and HDL anchor on the 
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cell surface of distinct cells and deliver bound ether lipid gradually, since both albumin and HDL 
can interact to specific saturable sites on the cell surface releasing selected ligands [103,104]. 
In spite of controversial experimental support, endocytosis or passive diffusion do not 
explain the general observation that ET-18-OCH3-sensitive cells take up significant amounts of 
the ether lipid while resistant cells do not. In this regard, flow cytometry analysis with 
fluorescein-labeled albumin showed no correlation between endocytosis and ET-18-OCH3 
uptake [11]. Furthermore, Zoeller and co-workers [84], using ethyl methanesulfonate as mutagen 
[105], isolated mutant strains from the murine, macrophage-like cell line RAW 264.7, that were 
resistant to the cytotoxic effect of ET-18-OCH3, and found no differences in both receptor-
mediated and fluid-phase endocytosis between ET-18-OCH3-resistant mutants and the ET-18-
OCH3-sensitive parent cells, whereas the parent cells took up significant amounts of ET-18-
OCH3 and the mutant cells did not. Thus, ET-18-OCH3 appears to be taken up through a more 
specific process than general endocytosis. Interestingly, hybrids generated from the fusion of 
ET-18-OCH3-uptake RAW competent cells with the uptake-deficient RAW mutants were able to 
take up ET-18-OCH3 in similar proportions as the uptake competent cells, suggesting that the 
mutations associated with these mutants are recessive [84]. 
It has been found that suramin, a broad-specificity membrane impermeable inhibitor of 
ligand-receptor interactions [106-111] inhibited both ET-18-OCH3 uptake and ET-18-OCH3-
induced apoptosis in human leukemic cells [11], suggesting that ET-18-OCH3 can interact with a 
cell surface protein involved in the transport of the ether lipid inside the cell. As ET-18-OCH3 is 
taken up by tumor cells at much higher levels than normal cells, it could be envisaged that a 
cellular structure, absent or present in low basal amounts in normal cells, but synthesized in 
higher amounts or appropriately modified in tumor cells, is responsible for the ET-18-OCH3 
uptake. It is interesting to note that there is no efflux of ET-18-OCH3 from preloaded cells, 
suggesting a tight association of the drug with cellular structures inside the cell [95]. In this 
regard, a very recent report indicates that a photoactivatable analogue of ET-18-OCH3 is able to 
interact with two cytosolic proteins of MCF-7 human breast cancer cells of molecular masses of 
47 and 170 kDa [112]. 
Binding assays with the ether lipid ET-18-OCH3 are complicated by the unspecific 
binding of the ether lipid to membrane that might hamper the detection of a putative specific 
binding to a hypothetical receptor or transporter, which could be ultimately related to the 
triggering of the biological activities of ET-18-OCH3. This problem is inherent to the lipidic 
nature of ET-18-OCH3. Thus, binding assays with the structural-closely related PAF molecule 
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are rather problematic due to a high unspecific binding [113], despite that PAF is well known to 
exert its biological effects through its interaction with a specific receptor [114]. Because of its 
structural similarity with PAF, the possibility that ET-18-OCH3 might enter cells and act via the 
PAF receptor might be discussed. However, ET-18-OCH3 uptake and cytotoxicity proceed via a 
mechanism independent of the interaction of ET-18-OCH3 with a PAF receptor. The evidence 
for this is manifold: 
a) ET-18-OCH3 is active and is incorporated by cells devoid of PAF receptors, such as 
HL-60 cells [11]. Interestingly, PAF receptors develop following granulocytic 
differentiation of HL-60 cells [115,116], when these cells become resistant to the 
ether lipid and do not incorporate the drug [11,82,117,118]. 
b) Lack of correlation between the presence of PAF receptor and ET-18-OCH3 uptake 
and cytotoxicity [11,117-119]. 
c) Neither PAF nor PAF antagonists prevent ET-18-OCH3 uptake and cytotoxicity 
[11,118-120]. 
d) PAF does not induce apoptosis in ET-18-OCH3 sensitive cells [11,118]. 
e) The affinity of the PAF receptor for ET-18-OCH3 was about 5000 times smaller than 
for the natural PAF lipid [118]. 
We favor the notion that a still unidentified cell surface protein can be involved in the 
specific incorporation of ET-18-OCH3 into target cells. This putative protein should be either 
expressed or modified selectively in transformed cells. Thus, non-transformed 3T3 cells were 
resistant to the apoptotic action of ET-18-OCH3 and incorporated only small amounts of the 
ether lipid, while upon transformation with SV40, these cells became sensitive to ET-18-OCH3 
and incorporated high amounts of the lipid [11]. Likewise, human leukemic HL-60 cells 
incorporate high amounts of ET-18-OCH3 and are sensitive to its apoptotic action, whereas 
following dimethyl sulfoxide (DMSO) treatment HL-60 cells are differentiated towards cells 
with features of normal non-transformed mature neutrophils [121], and in this differentiated state 
the uptake of the ether lipid was decreased as well as the sensitivity to the drug [11,82,117,118]. 
These data indicate that the action of the ether lipid is specific for tumor cells and that both 
cellular uptake and ET-18-OCH3-induced apoptosis are dependent on the malignant state of the 
cells (Fig. (5)). 
ET-18-OCH3 preferentially accumulates in the plasma membrane of transformed cells 
[88,122,123]. Taken together, the data support a putative ether lipid uptake mechanism 
consisting in two steps: a) ET-18-OCH3 binds first in a rather unspecific way to the outer layer of 
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the plasma membrane from which can be washed off by repeated washings or by BSA 
extraction; b) the ether lipid is flipped across the plasma membrane, being translocated into the 
cytoplasmic leaflet of the lipid bilayer, through still unidentified inwardly directed transporters 
or flippases. 
 
7. ET-18-OCH3 metabolism 
ET-18-OCH3 is a very metabolically stable compound, in comparison with its natural 
counterparts alkyl-lyso-phosphatitdylcholine and PAF. In tumor cells in culture, 98% of ET-18-
OCH3 remained unmodified after 24-h incubation [124]. Theoretically, ET-18-OCH3, as an 
alkyl-ether-phospholipid, can be metabolized through three major pathways (Fig. (6)): i) 
cleavage of the alkyl group, with formation of 1-lyso-2-O-methyl-phospholipid and stearyl 
alcohol; ii) phospholipase C (PLC) hydrolysis, with formation of 1-O-alkyl-2-O-methylglycerol 
and phosphocholine; and iii) phospholipase D (PLD) hydrolysis, with formation of 1-O-alkyl-2-
O-methyl-phosphatidic acid and choline. However, the ether lipid is not a substrate for PLA2 due 
to the ether alkyl bond in C2. 
In 1964, Tietz, Lindberg and Kennedy [125] discovered an enzyme termed glyceryl-ether 
monooxygenase, which has been also named O-alkyl glycerol monooxygenase, 1-O-alkyl-
cleavage enzyme, glyceryl etherase, glyceryl ether hydroxylase, or glyceryl ether oxidase. It is a 
membrane-bound protein that specifically cleaves the ether bond in glyceryl ethers. The enzyme 
inserts one oxygen atom of an oxygen molecule into the glyceryl ether substrate, hydroxylating 
the α-carbon atom of the lipid carbon chain, and subsequently cleaving the O-alkyl bond to the 
glycerol moiety and the respective aliphatic alcohol. Since high levels of glyceryl ethers are toxic 
to some cells, the glyceryl-ether monooxygenase plays an important role in regulating the levels 
of these ethers. In tissues in which the ether levels are low, as in human liver, the glyceryl-ether 
monooxygenase levels are high. Because ET-18-OCH3 exerts selective effects on tumor cells, 
attempts were made to explain this selectivity by a higher degradation of the ether lipid in 
normal cells. This notion was supported by the finding that some neoplastic tissues were found 
to have low levels of the glyceryl-ether monooxygenase [33]. However, it soon turned out no 
correlation between sensitivity of the cells to AEPs and activity of this enzyme [126,127]. Now, 
it is widely accepted that ET-18-OCH3 is not metabolized in most cells by glyceryl-ether 
monooxygenase [128,129], but appears to be metabolized very slowly by PLC activity to 
produce 1-O-octadecyl-2-O-methyl-rac-glycerol (OMG) [87,127,130-132]. This latter 
metabolite could also be generated by the action of a PLD activity followed by phosphatidate 
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phosphohydrolase, like occurring with natural phospholipids [124,133], and it has been found 
that PLD activity participates also in the metabolism of ET-18-OCH3 [124]. It has been 
hypothesized that the OMG metabolite, found in trace amounts in tumor cells, could be 
responsible for the cytotoxic action of ET-18-OCH3, due in part to the protein kinase (PKC) 
inhibitory action of OMG [131]. However, this notion is not sustainable at all, since: i) 
metabolism of ET-18-OCH3 by PLC or by PLD/phosphatidate phosphohydrolase occurs only at 
very low rates (less than 2% after 24-h incubation), if at all, in both tumor epithelial and 
leukemic cells [87,117,127,130-132,134]; ii) OMG does not exert antitumor activity by itself on 
leukemic cells in vivo or in vitro [11,117,133,135]; iii) lack of correlation between the quantity 
of OMG produced and sensitivity of the cell to ET-18-OCH3 [127]; and iv) AEP analogues 
unable to be metabolized by PLC are effective anticancer agents [134,136,137]. All of the above 
evidences also argue against metabolism being an obligatory step in the antiproliferative and 
cytotoxic effects of ET-18-OCH3. In this regard, in several cell lines, there is no correlation 
between the extent of metabolism of ET-18-OCH3 and susceptibility to its growth-inhibitory and 
cytotoxic effects [127]. Also, ET-18-OCH3 metabolism was negligible in human leukemic HL-
60 and K562 cells (1-2%) or in human colon carcinoma HT29 cells (2.5%) [124]. Taken 
together, these data indicate that ET-18-OCH3 is active per se and not a prodrug. 
Ether lipids show high specific cytotoxicity in vitro on a wide variety of experimental 
tumors, but only moderate activity in vivo. One reason for this lack of activity in the whole 
animal might be a high degree of metabolic degradation in vivo. In this regard, some metabolism 
has been suggested to be present in vivo, as very little of the intact compound was eliminated 
with urine and feces, and very low levels were found in tissues [138]. A reduced metabolic 
turnover and thus a slight enrichment of ET-18-OCH3 was found in tumor tissue in in vivo assays 
[139]. Unlike tumor cells, cultured rat hepatocytes, however, can degrade ET-18-OCH3, and 
about 35% and 59% of total radiolabeled [3H]ET-18-OCH3 was metabolized by liver cells after 6 
and 24 h incubation, respectively [124]. A variety of labeled metabolic products of ET-18-OCH3 
were found, including 1-O-alkyl-2-O-methyl-phosphatidic acid > 1-O-alkyl-2-O-methyl-glycerol 
> stearyl alcohol, as products of direct metabolism through the action of the enzymes depicted in 
Fig. (6), and phosphatidylcholine > triglycerides > fatty acids, as products of secondary 
metabolism [124]. Only very low amounts of stearoyl glycerol (0.9%), the direct product of the 
action of glyceryl-ether monooxygenase on ET-18-OCH3, was recovered in hepatocytes, 
suggesting that this is a minor metabolic route in the ET-18-OCH3 metabolism in hepatocytes. 
Taken together, the current data indicate that ET-18-OCH3 is not a substrate for glyceryl-ether 
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monooxygenase, and only negligible amounts of the metabolic product generated by this 
metabolic route are found in hepatocytes. Thus, the metabolism of ET-18-OCH3 is basically due 
to the action of PLC and PLD activities. Because phospholipases C and D are abundant not only 
in liver, but also in other tissues and cell types (lung, heart, leukocytes, etc.) [140-143], they 
might contribute to the degradation of ET-18-OCH3 given systemically. 
 
8. Antitumor activity 
ET-18-OCH3 shows an antitumor effect both in vitro and in vivo, and is considered as a 
standard and prototype for other ATLs with similar antineoplastic activities. The antitumor effect 
of ET-18-OCH3 is based mainly on two different mechanisms which can act synergistically 
against neoplastic growth. ET-18-OCH3 enhances the tumoricidal activity of macrophages 
[144,145], and exerts a direct cystostatic and cytotoxic effect on tumor cells [9-11,146-150]. 
However, the direct cytotoxicity effect of ET-18-OCH3 seems to be the major action for its 
antitumor activity in vivo, and the proapoptotic effect of ET-18-OCH3 accounts for the cytotoxic 
activity of the ether lipid [9-11,150]. This combination of a stimulatory effect on host defense 
cells and a direct destructive effect on neoplastic cells in one molecule makes ET-18-OCH3 a 
potentially effective antitumor drug. The cytotoxicity of ET-18-OCH3 is believed to occur 
independently and by a different mechanism from the cytostatic effects of the drug [148,149]. In 
addition to potentiate host defenses against tumor, ET-18-OCH3 has been reported to affect four 
major parameters that make this AEP a potentially potent antitumor drug, namely (Figure (7)): a) 
inhibition of tumor cell proliferation; b) induction of apoptosis in tumor cells; b) inhibition of 
metastasis; d) inhibition of angiogenesis. Also, ET-18-OCH3-induced differentiation has been 
reported in some tumor models that could be important for the so named differentiation therapy. 
Nevertheless, whereas the cytostatic and proapoptotic effects of ET-18-OCH3 are well 
established, its role in modulating metastasis and differentiation is questionable at present. 
 
8.1. Inhibition of proliferation and cell cycle effects 
 ET-18-OCH3 treatment does not interfere with the S phase of the cell cycle, but leads to 
the accumulation of cells in G2/M [148,151-156]. ET-18-OCH3 inhibits cell division without 
concurrent inhibition of nuclear division, leading to multinucleate cell formation, and subsequent 
cell death through apoptosis [157,Mollinedo, F., del Canto-Jañez, E., Verhaegen, S. and Gajate, 
C., unpublished data]. ET-18-OCH3-treated cells proceeded through the full cell cycle, but failed 
to undergo cell division (mitosis), and instead accumulated as tetraploid or octaploid cells in the 
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G0/G1 phase of the cell cycle [157,Mollinedo, F., del Canto-Jañez, E., Verhaegen, S. and Gajate, 
C., unpublished data]. Inhibition of cell growth by ET-18-OCH3 resulted from inhibition of 
cytokinesis [157,Mollinedo, F., del Canto-Jañez, E., Verhaegen, S. and Gajate, C., unpublished 
data]. Also, a number of reports show that ET-18-OCH3-treated cells are arrested in the G0/G1 
phase of the cell cycle [148,153,154,157]. It has been reported that ET-18-OCH3 inhibits PC 
synthesis [39,158] that arises from the inhibition of CTP:phosphocholine cytidylyltransferase 
(CCT) [159]. The addition of LPC provided an exogenous source of cellular phospholipid, 
restoring PC de novo biosynthesis [159] (see below), and partially reduced the number of 
apoptotic cells following ET-18-OCH3 treatment [157]. Boggs and co-workers [148] found that 
LPC addition prevented ET-18-OCH3-dependent accumulation of cells in G2/M and the 
subsequent apoptotic response. However, LPC did not overcome the ET-18-OCH3-dependent 
G0/G1 block, although the growth-arrested cells remained viable, indicating that restoring of PC 
synthesis by supplementation with LPC overrides the cytotoxic but not the cytostatic activity of 
ET-18-OCH3 [148]. Microtubule assembly appears to be unaffected by exposure to ATLs [160], 
although F-actin filaments could be collapsed [4,157]. At present, the mechanisms by which ET-
18-OCH3 arrests cell cycle progression and inhibits cytokinesis have yet to be explored in detail. 
 
8.2. Induction of apoptosis 
 A key finding in the elucidation of the processes involved in the antineoplastic effect of 
ET-18-OCH3 was the demonstration in 1993 by Mollinedo and co-workers [9] in Madrid (Spain) 
and Diomede and co-workers [10] in Milan (Italy) of its proapoptotic effect on cancer cells. This 
apoptotic action appears to be the major antitumor effect of ET-18-OCH3 [9,10,11,150]. The 
apoptotic response was optimally induced after treatment with 3-5 µg/ml (6-10 µM) of ET-18-
OCH3 [164]. Following these pioneering studies, subsequent reports have shown that other ATLs 
are also able to induce an apoptotic response in tumor cells [19,161,162]. We have also found 
that ET-18-OCH3 is a potent inducer of apoptosis in cancer cells, but spares normal cells [11]. 
Based on our own data on the molecular mechanisms by which ET-18-OCH3 engages selectively 
the suicide apparatus, we propose a two-step model for the proapoptotic action of ET-18-OCH3 
on cancer cells that represents a new mechanism of action for an antitumor drug (Fig. (8)). A 
first and crucial event is the selective incorporation of ET-18-OCH3 into the target tumor cell, 
and we hypothesize that a yet unidentified cell surface protein present or appropriately modified 
in cancer cells, but not in normal cells, would be responsible for the selective incorporation of 
the ether lipid into the malignant cell [11,12]. Then, ET-18-OCH3 stimulates from inside the cell 
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a cell death receptor Fas/CD95-mediated apoptotic signaling pathway to induce apoptosis, 
independently of the natural ligand FasL. This second step requires the presence of the cell death 
receptor Fas/CD95 and is not selective for cancer cells, as ET-18-OCH3-microinjected normal 
human fibroblasts undergo apoptosis [12]. Thus, the apoptotic action of ET-18-OCH3 appears to 
take advantage of some plasma membrane components uniquely expressed or modified in the 
cell surface of transformed cells as well as of the efficient Fas cell death signaling route present 
in both cancer and normal cells. The above model is based on the following evidences 
[11,12,112,162]: a) cancer cells take up significant amounts of the ether lipid, but normal cells 
do not; b) disruption of ligand-receptor interactions by suramin treatment inhibits both ET-18-
OCH3 uptake and cytotoxicity; c) ET-18-OCH3 is able to interact with cellular proteins; d) ET-
18-OCH3 does not induce apoptosis in normal fibroblasts, which are unable to incorporate the 
drug, but these cells rapidly undergo apoptosis following microinjection of the ether lipid; e) ET-
18-OCH3 only induces apoptosis in Fas/CD95-containing cells; f) Fas/CD95-deficient cells are 
spared from the apoptotic effect of ET-18-OCH3, but they become sensitive to the apoptotic 
action of the ether lipid after transfection with Fas; g) Fas/CD95-expressing cells that do not take 
up ET-18-OCH3 are unaffected by the ether lipid when this is added exogenously, but they 
undergo rapid apoptosis following microinjection of ET-18-OCH3; h) clustering and capping of 
Fas is rapidly observed following ET-18-OCH3 treatment and takes place before the onset of 
DNA fragmentation. A recent report also supports the participation of Fas/CD95 in the 
mechanism of action of ATL analogues, involving a Fas-FADD-mediated signaling pathway 
[163]. The clustering, capping and subsequent activation of Fas/CD95, independently of FasL, 
by intracellular ET-18-OCH3 represents a novel mechanism of action for an antitumor drug. 
Thus, two main requirements must be fulfilled in order to elicit an apoptotic response upon ET-
18-OCH3 ether lipid treatment, namely: a) ether lipid uptake, and b) Fas/CD95 presence in the 
target cell. Cells that fail to accomplish efficiently one or both requirements are unable to 
undergo apoptosis upon ET-18-OCH3 treatment. Normal cells are resistant to the ether lipid 
action due to their inability to incorporate enough amounts of ET-18-OCH3 required to induce 
apoptosis, whereas a wide number of cancer cells incorporate high amounts of this ether lipid 
[12]. Cells that do not express Fas/CD95 fail to undergo apoptosis after incubation or 
microinjection with ET-18-OCH3, in spite of achieving high intracellular concentrations of the 
ether lipid [12]. Cells expressing Fas/CD95 at their cell surface, but unable to take up the ether 
lipid, are resistant to undergo apoptosis upon exogenous addition of ET-18-OCH3, but become 
sensitive to the drug when the ether lipid is microinjected [12]. This indicates that an interaction 
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between ET-18-OCH3 and Fas/CD95 at the external side of the cell surface is not involved in the 
onset of the ether lipid-induced apoptosis and that ET-18-OCH3 must be incorporated into the 
cell to trigger a Fas/CD95-mediated apoptotic response. 
In recent studies from our and other groups [164-167], a number of additional apoptotic 
signaling pathways have been implicated in the apoptotic response elicited by ET-18-OCH3, 
including: persistent activation of c-Jun NH2-terminal kinase (JNK), disruption of the 
mitochondrial transmembrane potential (∆Ψm), release of cytochrome c from mitochondria, 
caspase-3 activation. ET-18-OCH3 is also able to induce the expression of fos and jun proto-
oncogenes and to activate the transcription factor AP-1 in human leukemic cells [164,168]. We 
have observed that the steady state mRNA level of c-jun was dramatically increased on ET-18-
OCH3 treatment [168]. Antisense oligonucleotides directed against c-jun blocked ET-18-OCH3-
induced apoptosis, indicating a role for c-Jun in this apoptotic response [164]. This notion was 
further confirmed using a dominant-negative mutant of c-jun that inhibited ET-18-OCH3-
induced apoptosis [166]. The role of c-Jun in the cascade of events triggered by ET-18-OCH3 
remains to be elucidated. C-Jun is a major component of the transcription factor AP-1, but 
because ET-18-OCH3-induced apoptosis does not require protein synthesis [165], it can be 
envisaged the involvement of c-Jun in transcription-independent events leading to cell death. The 
weak induction of c-fos by ET-18-OCH3 was not related to the induction of apoptosis, as 
antisense oligonucleotides against c-fos did not prevent ET-18-OCH3-induced apoptosis [164]. 
This is in agreement with evidence from c-Fos-deficient mice demonstrating that c-fos is not 
essential for the induction of apoptosis [169]. We have also found that ectopic overexpression of 
bcl-2 or bcl-xL prevents apoptosis induced by ET-18-OCH3, but not its cellular uptake [11], 
suggesting that high levels of Bcl-2 and Bcl-XL can block the intracellular signaling route 
leading to cell death triggered by ET-18-OCH3. However, p53 is dispensable for ET-18-OCH3-
induced apoptosis as HL-60 cells are very sensitive to the apoptotic action of ET-18-OCH3 
[9,11] and do not express p53 [170]. On the other hand, the apoptotic effect of ET-18-OCH3 is 
not related to rapid changes in cytosolic free calcium concentration [118]. 
 
8.3. Antiangiogenic effect 
In the early 1970s, Folkman proposed antiangiogenic therapy as a method to block tumor 
growth [171,172], and subsequent research evidenced that neovascularization plays an important 
role in the growth and spread of tumors. There is now strong evidence that inhibition of 
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angiogenesis can severely restrict tumor growth and can be an interesting approach to cancer 
treatment [172-174]. 
Using the human microvascular endothelial cell line HMEC-1 [175], Candal and co-
workers [176] found that ET-18-OCH3 reversibly inhibited formation of HMEC-1 tubules, used 
as an in vitro assay for angiogenesis. This antiangiogenic activity was shown at doses higher 
than 43 nM. ET-18-OCH3 exerted additional effects on HMEC-1 when used at lower 
concentrations (32 nM), namely [176]: a) a decrease in the expression of several known adhesion 
molecules, including: integrin beta-1 (CD29), involved in wound healing, tissue invasion and 
tumor metastasis; CD44 (HCAM, homing-associated cell adhesion molecule), involved in 
lymphocyte homing; and CD54 (ICAM-1, intercellular adhesion molecule-1), involved in 
neutrophil transmigration and the inflammatory response; b) a decrease in the cell-to-cell tight 
association. ET-18-OCH3 was also found to inhibit in vitro the ability of bovine adrenal capillary 
endothelial cells to migrate toward the angiogenic agent basic fibroblastic growth factor (bFGF), 
using a Boyden chamber assay [177]. This in vitro antiangiogenic activity was detected at ether 
lipid doses ranging between 8-200 nM, however ET-18-OCH3 enhanced by itself microvascular-
cell migration when used at doses higher than 200 nM. Such biphasic effects have also been 
reported for some inhibitors of angiogenesis, like thrombospondin [178], likely due to the 
capacity of thrombospondin to stimulate multiple receptors with differing affinities, some 
inhibitory and some stimulatory. The visualization of neovascularization in vivo, in corneas 
receiving bFGF implantation as a potent neovascularization inducer, also proved the 
antiangiogenic capability of ET-18-OCH3 [177], even though there was certain variability in the 
response. Rats received intraperitoneal injections of 20 mg ET-18-OCH3/kg, twice daily, and 
then found that 5 out of 9 animals receiving ET-18-OCH3 showed no corneal neovascularization, 
3/9 showed intermediate inhibition, and only 1/9 failed to show any inhibition [177]. An 
antiangiogenic effect has also been reported for a phosphonate-derived ether lipid [19]. Unlike 
ET-18-OCH3, other related lipids have been reported to be proangiogenic, including the 
phospholipid PAF [179], 1-butyryl-glycerol [180] as well as the fatty-acid amide erucamide 
[181]. 
 
8.4. Anti-invasive effects 
The metastatic spread of tumor cells from the primary tumor is the most prominent 
problem in treating cancer patients. A number of reports have shown the ability of ATLs to 
prevent invasion of tumor cells into surrounding tissues in vivo or into reconstituted basement 
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membrane matrices in vitro [152,160,182-188]. However, no conclusive data have been obtained 
so far, and a molecular explanation for this action is still lacking. Furthermore, antithetic effects 
on invasion have also been reported, namely ET-18-OCH3 inhibits invasion of constitutively 
invasive cells [152,184,189,190], whereas it induces invasion of otherwise non-invasive cells 
[191,192]. Modification of glycoprotein processing, especially via changes in sialyltransferase, 
episialin-mediated neutralization of E-cadherin, membrane changes and induction of host tissue 
resistance have been suggested as possible explanations for the modulation of tumor cell 
invasiveness by ATLs [88,160,183,192-196], but clear-cut correlations remain difficult to 
establish. Furthermore, because of the pleiotropic activity of ATLs, it is still questionable 
whether modulation of invasiveness is a major action of ATLs or a rather secondary response 
dependent on cell type and experimental conditions. 
 
8.5. Effect on cell differentiation 
 It has been reported that ET-18-OCH3 is able to induce differentiation on human and 
mouse leukemic cell lines, including HL-60, U937, KG1 and M1 cells [197,198]. Other ATLs 
have also been reported to induce cell differentiation [199,200]. However, these studies were 
mostly based on morphological observations and analysis of a reduced number of biochemical 
assays. In contrast, some parameters that are normally associated with myeloid differentiation 
are not detected following ET-18-OCH3 treatment [201;Gajate, C. and Mollinedo, F., 
unpublished data], questioning the role of ET-18-OCH3 in inducing myeloid differentiation of 
leukemic cells. 
 
9. Effect of ET-18-OCH3 on phospholipid metabolism and signal transduction 
 The cytostatic and apoptotic effects of the ether lipid ET-18-OCH3 have been explained 
by its action on PC metabolism and on the apoptotic signaling, leading to the notion that the two 
major targets of ET-18-OCH3 are CTP:phosphocholine cytidylyltransferase (CCT) and the cell 
death receptor Fas/CD95 (Fig. (9)), key proteins in the de novo synthesis of PC and in the 
initiation of an apoptotic response, respectively [202-205]. Also ET-18-OCH3 seems to affect 
survival signaling and this can be of major importance in potentiating ET-18-OCH3-induced 
apoptosis. 
 
9.1. Modulation of phospholipid metabolism 
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Phosphatidylcholine (PC) is essential for cell survival because it is a major structural 
building block of biological membranes and the precursor to other abundant membrane 
phospholipids: phosphatidylethanolamine [206] and sphingomyelin [207]. In addition PC is the 
precursor of second messengers following stimulation of cell surface receptors. In 1979, 
Modolell and co-workers [39] reported that ET-18-OCH3-treated Meth A sarcoma cells had 
reduced levels of PC. Subsequently, several groups have showed that ET-18-OCH3 inhibits 
choline incorporation into PC [208-211]. CTP:phosphocholine cytidylyltransferase (CCT), 
which catalyzes the formation of CDP-choline, has long been recognized as the key enzyme 
controlling the PC biosynthetic pathway [202-204] and plays a determinant role in regulating de 
novo membrane phospholipid accumulation. CCT is necessary for cell survival [212-215], and 
absolutely requires the presence of specific lipids for activity [216,217]. CCT is activated by 
interactions with membranes containing diacylglycerols [218,219], fatty acids [220], or deficient 
in phosphatidylcholine [221,222], and is potently inhibited by sphingosine [223] and LPC [159]. 
CCT activity is also regulated by phosphorylation, with reduced CCT activity correlating with 
increased phosphorylation of the protein [224]. In addition, the soluble form of CCT is highly 
phosphorylated whereas the unphosphorylated CCT exhibits a greater degree of membrane 
association in cells [225-228]. cDNAs that encode for CCT, now named CCTα, have been 
identified and sequenced in rat [229], hamster [230], mouse [231], and human [232], and there 
are only minor differences among these mammalian cDNAs. Recently, Lykidis and co-workers 
[233] have identified and sequenced a human cDNA that encoded a distinct CCT isoform, called 
CCTβ, that is derived from a gene different from that encoding CCTα. CCTα protein is thought 
to be an intranuclear protein [226-228,230,234], although other additional subcellular 
localizations have been reported, such as Golgi, endoplasmic reticulum and transport vesicles 
[235,236], whereas CCTβ lacks the nuclear targeting sequence and the phosphorylation domain 
of CCTα, suggesting that the new isoform differs from CCTα with regard to its subcellular 
localization and regulation [233].  
 The LPC non-metabolizable analog ET-18-OCH3 was found to inhibit choline 
incorporation into PC as well as total phospholipid synthesis as a result of CCT inhibition. The 
inhibition of PC synthesis seems to be an universal effect of ET-18-OCH3 and other ATLs on 
cells [39,208-211,237-243], suggesting that this interference with PC metabolism may be 
responsible for the biological effects of ATLs. ET-18-OCH3 and HPC mimic LPC, a 
physiological regulator of CCT activity, reducing the CDP-choline formation in intact cells and 
inhibit purified CCT in an in vitro assay by competing for the lipid activator site of the enzyme 
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[148,159,161]. Supplementation of the medium with LPC provides an alternative pathway to PC 
formation, as LPC is taken up rapidly by cultured mammalian cells and acylated to form PC 
[244], thus circumventing the de novo PC biosynthetic pathway, and prevents apoptosis induced 
by either ET-18-OCH3 [148] or HPC [161]. The ability of LPC to prevent ether lipid-induced 
apoptosis supports the idea that maintenance of the bulk supply of membrane phospholipid is the 
determining factor in averting the drug-induced apoptosis program, rather than a specific role for 
CCT. However, it cannot be excluded the possibility that LPC inhibits uptake of the 
antineoplastic ether lipids. Interestingly, exogenous LPC supplementation was unable to restore 
the proliferation of ET-18-OCH3-treated cells [148,161], indicating that ET-18-OCH3 also has 
cytostatic properties that are not related to its interference with PC biosynthesis. This inability of 
LPC to override the cytostatic effect of ET-18-OCH3 suggests that uptake of the ether lipid is not 
completely impaired in the presence of LPC. Likewise, addition of oleic acid, a potent CCT 
activator, restores PC synthesis to ET-18-OCH3-treated MCF-7 cells, but does not reverse the 
inhibition of cell growth [241].  In addition, overexpression of CCT in HeLa cells also prevented 
ET-18-OCH3-induced apoptosis, as well as acylation of exogenous LPC, which circumvented the 
requirement for CCT activity [245]. However, neither CCT overexpression nor LPC 
supplementation allowed the HeLa cells to proliferate in the presence of ET-18-OCH3, further 
supporting that the cytostatic action of ET-18-OCH3 was independent on its effect on membrane 
phospholipid synthesis activity [245]. This contrasts with studies carried out with HPC, where 
exogenous LPC prevents HPC-induced apoptosis and restores proliferation of HPC-treated cells 
[161]. These data indicate that ET-18-OCH3 and HPC, though sharing several actions, possess 
distinguishing structural features that make them to affect different targets and signaling 
pathways. Jackowski’s group has proposed that CCT is a major target for ET-18-OCH3 and 
HPC, acting as LPC analogs, and the subsequent interruption of PC synthesis at the CCT step is 
the primarily physiological imbalance that accounts for the cytotoxic action of these drugs. This 
action together with the inability of these drugs to be converted to PC or to be significantly 
metabolized by cells [95,127,135,218,246] could account for their cytotoxicity. However, these 
data raise the question whether the effect of ET-18-OCH3 on PC metabolism can explain the 
selective action of this drug on tumor cells. Also the fact that CCT overexpression bestows ET-
18-OCH3 resistance raises the question of whether or not the differences between sensitive and 
resistant cells can be attributed to differences in the level of CCT expression. Although this issue 
has not been addressed, it seems unlikely that differences in CCT expression accounts for the 
large range of drug sensitivity among cell types.  
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 In an attempt to explain the putative ET-18-OCH3 selectivity, Vogler and co-workers 
[247] reported a substitution in the sequence of CCT at nucleotide 751 from A in the sensitive 
HL-60 cell line to G in the resistant K562 cell line, that resulted in a change in amino acid 
number 251 from lysine in the HL-60 enzyme to glutamic acid in the K562 enzyme. These 
authors hypothesized that this mutation might result in a weaker affinity of ET-18-OCH3 to CCT 
in K562 cells, accounting for the resistance to the apoptotic action of the ether lipid. However, in 
a preliminary study with a wide number of cells, both resistant and sensitive to ET-18-OCH3, we 
could not find experimental support to this notion as we did not detect the above reported 
mutation in a wide number of ET-18-OCH3-resistant and sensitive cells (Mollinedo, F. and 
Gajate, C., unpublished data).    
 Some evidences question a primary association of an alteration in the PC metabolism 
with the antitumor action of ET-18-OCH3. The induction of apoptosis by ET-18-OCH3 is very 
rapid in certain leukemic cells, such as HL-60 cells, occurring after 3 h of treatment [164], 
whereas changes in PC metabolism require much longer incubation times. Also, several reports 
indicate a lack of correlation between interference with phospholipid metabolism and the 
sensitivity of different cell lines to the blockade of proliferation by ET-18-OCH3 [241,248,249]. 
In this regard, ET-18-OCH3 was reported to inhibit PC content in both MCF-7 cells, which are 
sensitive to the growth inhibitory effects of ET-18-OCH3, and A549 cells which are relatively 
resilient to the compound [241]. Zhou and Arthur [241] found that changes in PC content were 
detected after inhibition of proliferation in MCF-7 cells induced by ET-18-OCH3, and although a 
decrease in the PC content was observed in ET-18-OCH3-treated A549 cells their proliferation 
was identical to that of untreated cells [241]. These authors also found a clear dissociation 
between the inhibition of PC synthesis and the inhibition of cell growth by ET-18-OCH3 in a 
number of epithelial tumor cells [241]. 
It has been also reported that ET-18-OCH3 inhibits acyl-CoA acyltransferase activity 
(IC50, 80 µM) [158]. As the concentration of ether lipid necessary to inhibit acyl-CoA 
acyltransferase is much higher than the drug dose required to exert its cytostatic and cytotoxic 
affects, the participation of this enzyme in the antitumor activity of the ether lipid can be ruled 
out. Although ET-18-OCH3 treatment resulted in decreased incorporation of fatty acids into a 
number of phospholipids, notably phosphatidylcholine, however increased incorporation of fatty 
acids into other phospholipids, such as phosphatidylethanolamine has been detected, and again 
there was a lack of correlation between the incorporation of fatty acids into PC or other 
phospholipids and the action of ET-18-OCH3 on cells [241,248,249]. ET-18-OCH3 has also been 
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reported to be a potent inhibitor of CoA-independent transacylase (IC50, 0.5 µM), using 
microsomes of human leukemic cells (HL-60 and U937 cell lines), and complete inhibition was 
observed at 3 µM [250]. Additional inhibitors of this enzyme where found to induce apoptosis 
[250], suggesting that this inhibitory action could be involved in the cytotoxic action of the ether 
lipid. CoA-independent transacylase is an enzyme responsible for the movement of arachidonate 
between phospholipid molecular species. This enzyme transfers arachidonate from the sn-2 
position of 1-acyl-containing phospholipids, such as 1-acyl-2-arachidonoyl-sn-glycero-3-
phosphocholine, to a suitable lyso-phospholipid acceptor, such as 1-alkyl-2-lyso- sn-glycero-3-
phosphocholine and 1-alkenyl-2-lyso-sn-glycero-3-phosphoethanolamine [251-253], and this is 
thought to be the mechanism by which inflammatory cells move arachidonate into specific 
phospholipid pools [254]. Many cancer cells contain high levels of 1-ether-linked phospholipids 
[255,256], and it has been found a correlation between ET-18-OCH3 susceptibility and the ether 
lipid content of leukemia cells [257]. Winkler and co-workers [250] hypothesized that blocking 
CoA-independent transacylase would prevent arachidonate loading into 1-ether-linked 
phospholipid pools, and tentatively would influence cancer cell growth. However, the above 
inhibitory assays were not conducted in intact cells, but in microsomes, and again no correlation 
between changes in the movement of arachidonate into specific phospholipid pools and 
inhibition of proliferation in ET-18-OCH3-treated cells could be consistently observed [248]. In 
addition, Lu and Arthur [248] reported that although ET-18-OCH3 inhibited proliferation in 
human colon carcinoma T84 cells, the ether lipid led to an increase in the quantities of 
arachidonate and oleic acids incorporated into phospholipids, indicating that the net effect of the 
drug appears to be an activation of cellular acylation processes rather than their inhibition. 
On these grounds, no clear conclusions about the relationship between the interference of 
ET-18-OCH3 on lipid metabolism and its antiproliferative and cytotoxic effects can be drawn 
when a large number of cells are examined. The ether lipid actions on lipid metabolism seem to 
depend largely on the cell type and experimental conditions used, and some compensatory 
mechanisms that overcome initial lipid metabolism perturbations seem to exist. Also, in some 
tumor cells, the reduced incorporation of fatty acid in cellular phospholipids seemed to be a 
consequence of the inhibition of proliferation by ET-18-OCH3 rather than its cause. All these 
data make questionable that the interference in lipid metabolism is a primary and general cause 
for the inhibition of cell growth and cytotoxic action of ET-18-OCH3. 
 
9.2. Effects on apoptotic and survival signaling 
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 As described above ET-18-OCH3 behaves as a potent inducer of apoptosis and triggers 
rapidly an apoptotic pathway that involves: Fas/CD95, JNK signaling, mitochondria and caspase 
activation. However, in addition to be a potent inducer of apoptotic signaling, some reports 
suggest that ET-18-OCH3 can also inhibit survival signaling in tumor cells. This combination of 
apoptotic signaling enhancement and survival signaling inhibition makes ET-18-OCH3 a 
potential effective antitumor drug.  Apoptosis induction is under tight control of both apoptosis-
promoting and apoptosis-inhibiting signals [258,259]. In this context, stimulation of the JNK 
cascade has been associated with apoptosis induction, whereas activation of MAPK is essential 
for cell growth and differentiation and may counteract apoptotic signaling. The balance between 
the proapoptotic JNK pathway and the antiapoptotic MAPK cascade may be critical in the cell’s 
fate to die or to survive [258,259]. ET-18-OCH3 has been reported to be a potent activator of 
JNK [164,166], and to inhibit MAPK signaling [166,260]. 
 Other signaling pathways related to survival have also reported to be affected by ET-18-
OCH3. Phosphatidylinositol-specific phospholipase C (PI-PLC) has been implicated as playing a 
role in cell proliferation. Powis and co-workers [261] have shown that ET-18-OCH3 inhibits the 
in vitro activity of PI-PLC, whereas PC and PAF fail to inhibit this activity. ET-18-OCH3 
resulted to be a more potent inhibitor of membrane-associated PI-PLC activity (IC50<1 µM, 
when incorporated into labeled-phosphatidylinositol(4,5)bisphosphate substrate micelles, and 
IC50 of 5 µM when added directly to the enzyme assay) than of cytosolic PI-PLC [261], 
suggesting a putative isoform specificity in this inhibition, as PI-PLC-γ1 is mainly cytosolic and 
PI-PLC-β1 is over 80% membrane bound [262]. However, ET-18-OCH3 failed to inhibit 
phosphatidylcholine-specific PLC or PLD activity [261]. In a subsequent study, ET-18-OCH3 
was reported to inhibit the association of Gαq/11 with PLC-β1 [263]. Also, it was found that non-
small cell lung carcinoma (NSCLC) cell lines were more sensitive than small cell lung 
carcinoma (SCLC) cells to the antiproliferative effects of ET-18-OCH3, and the PLC-β1 protein 
levels were higher in SCLC cells compared with NSCLC cells [263], suggesting that increased 
PI-PLC-β1 expression may contribute to the resistance of the SCLC cell lines to ET-18-OCH3, 
although the relevance of this finding in relation to the cytostatic action of ET-18-OCH3 is not 
clear. 
In addition, ET-18-OCH3 has been reported to reduce the number of epidermal growth 
factor receptor (EGFR) sites without affecting the affinity of the receptors in human breast 
cancer cell lines [264], and this reduction in the epidermal growth factor binding capacity might 
be related to the ET-18-OCH3-induced inhibition of the growth of hormone-dependent breast 
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cancer cells. ET-18-OCH3 has also been shown to affect phosphatidylinositol-3-kinase (PI-3-
kinase), a signaling enzyme that interacts with receptor tyrosine kinases, and is involved via 
protein kinase B (PKB/Akt) in proliferative and survival responses [265]. The ether lipid ET-18-
OCH3 was found to inhibit immunoprecipitated or purified PI-3-kinase activity, from Swiss 
mouse 3T3 fibroblasts or bovine brain, with an IC50 of 35 µM [266]. This inhibition was non-
competitive with ATP. Other ATLs, like HPC and SRI 62.834, also inhibited PI-3-kinase activity 
with an IC50 of 48 and 42 µM, respectively [266]. ET-18-OCH3 was also found to inhibit PI-3-
kinase phosphorylation of endogenous phospholipid with an IC50 of 18 µM, when Swiss 3T3 
cells were grown in the presence of ET-18-OCH3, and to inhibit platelet-derived growth factor 
(PDGF)-dependent PI-3-phosphates formation in v-sis NIH 3T3 intact cells with an IC50 of 12.5 
µM [266]. However, Swiss 3T3 and v-sis NIH 3T3 cells are rather resistant to growth inhibition 
by ET-18-OCH3 with IC50 of 19 µM and 74.3 µM (determined under continuous exposure to the 
ether lipid for 7 days) respectively [261], and NIH 3T3 cells are rather resistant to undergo ET-
18-OCH3-induced apoptosis [11]. Therefore, the inhibitory action on PI-3-kinase does not seem 
to play a major role in the cytostatic and proapoptotic actions of ET-18-OCH3. However, it has 
been recently reported that a 1D-3,4-dideoxyphosphatidylinositol ether lipid is able to inhibit PI-
3-kinase and Akt activity as well as cell growth of NIH 3T3 cells [267]. 
On the other hand, ET-18-OCH3 increases the levels of reactive oxygen species 
[165,167,268] and stimulates membrane lipid peroxidation [269] in tumor cells, but it is not clear 
the contribution of these effects to the cytotoxic action of the ether lipid. 
 
9.3. Effects on heat shock proteins 
Heat shock proteins (Hsps), are molecular chaperones that bind non-native states of other 
proteins and assist them to reach a functional conformation [270]. Hsps are induced in response 
to a wide range of stresses, including heat shock and exposure to chemical agents, protecting 
cells from the deleterious effects of stress and allowing them to recover and survive [271]. Hsps, 
particularly Hsp70 and Hsp27, protect cells from most of apoptotic stimuli and are commonly 
overexpressed in human tumors, correlating in certain cancers their expression with poor 
prognosis and resistance to therapy [272]. 
In cultured normal rat astrocytes, ET-18-OCH3 has been found to promote a moderate 
induction of Hsp70, when used at low doses [273], suggesting that the ether lipid is able to 
induce a protective response in normal astrocytes. On the other hand, ET-18-OCH3 has also been 
reported to induce cell surface expression of Hsp70 without stimulating Hsp70 synthesis in the 
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human chronic myelogenous leukemia cell line K562 [274], which is highly resistant to the ether 
lipid action [150,159,275]. This is of importance as cell surface-expressed Hsp70 may function 
as a recognition structure for natural killer (NK) cells [276-278], and thereby enhance cell death 
through the host immune surveillance. The amount of cell membrane-bound Hsp70 was 
synergistically increased following treatment of K562 cells with a sublethal heat (41.8ºC) and 
subsequent ET-18-OCH3 incubation, resulting in a significantly enhanced sensitivity to lysis 
mediated by NK cells [279]. However, this up-regulation in Hsp70 cell surface and augmented 
sensitivity to NK cell-mediated lysis was not observed in normal peripheral blood lymphocytes 
and CD34+ progenitor cells [279]. On the other hand, it has been also reported that ET-18-OCH3 
promotes a translocation of Hsp27 from the cytoplasm to the nucleus that correlates with 
induction of apoptosis in BG-1 human ovarian carcinoma cells [280]. However, the 
accumulation of Hsp27 around the nucleus seems to be an indicator of induced resistance or a 
protection mechanism [281, 282]. The significance and putative clinical implications of these 
findings must await further experimentation in both in vitro and in vivo models.  
 
9.4. Effects on protein kinase C 
Protein kinase C (PKC) activity includes a family of ubiquitously distributed Ser/Thr protein 
kinases that play a crucial role in several important physiological processes, including cell 
proliferation and differentiation. Many pharmacological inhibitors of PKC induce apoptosis, 
suggesting that PKC activity could render cells more resistant to apoptotic inducing agents [283]. 
PKC belongs to a large family of closely related proteins with multiple subspecies. PKC 
isozymes have been classified into three groups: the classical isoforms that are activated by Ca2+ 
and diacylglycerol or phorbol esters, the novel PKC (nPKC) that are Ca2+ independent but are 
activated by diacylglycerol and phorbol esters, and the atypical PKCs (aPKC) that are not 
activated by Ca2+, diacylglycerol or phorbol esters [284,285]. 
A number of conflicting and contradictory reports have been published concerning the 
effect of ET-18-OCH3 on PKC activity, and its relationship with ET-18-OCH3-induced cytostatic 
and cytotoxic effects. These studies have to be interpreted cautiously, because so far most of the 
investigations on PKC activity by ether lipids have been performed under conditions suitable for 
testing calcium-dependent PKC activity, and therefore the putative action of ET-18-OCH3 can 
only be applied to these calcium-dependent PKC isoforms. ET-18-OCH3 has been reported to 
inhibit PKC in cell free-systems with artificial membrane structures, composed of liposomes 
consisting of a mixture of phosphatidylserine and diacylglycerol, as cofactors [48,286,287]. This 
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inhibition was described as competitive inhibition with respect to the phosphatidylserine binding 
site on the regulatory domain of the enzyme [287,288]. However, Heesbeen and co-workers 
[289] have demonstrated that ET-18-OCH3 can affect partially purified cytosolic PKC activity in 
different ways, depending on how the ether lipid is presented in the enzymatic assay. ET-18-
OCH3 inhibited PKC activity when added to a reaction mixture containing liposomes of 
phosphatidylserine and diacylglycerol; increased PKC activity when the ether lipid is present in 
mixed liposomes containing phosphatidylserine, diacylglycerol and increasing amounts of ET-
18-OCH3; and did not affect PKC activity when liposomes of ET-18-OCH3 were prepared and 
added separately to the liposomes of phosphatidylserine and diacylglycerol in the assay mixture. 
In this regard van Blitterswijk and co-workers [131] have also found no inhibition of PKC 
activity by the ether lipid when added as separate liposomes. To investigate the effect of ET-18-
OCH3 on PKC in intact cells, membranes of human leukemic cells were isolated before and after 
cell incubation with ET-18-OCH3 and PKC activity determined. Under these more physiological 
conditions it was observed that the ether lipid induced a 3-fold increase in PKC activity, but this 
increase in PKC activity was not a consequence of translocation or de novo synthesis of PKC 
[289]. In contrast, using a similar approach, Berkovic and co-workers [290] found that ET-18-
OCH3 induced about 30% reduction in PKC activity in intact cells without interfering with PKC 
translocation. The fact that PKC activity depends on the physical state of the lipid environment 
in different assay systems can explain these rather contradictory results. At any case, a putative 
role of PKC in ET-18-OCH3-induced cytostatic and cytotoxic effects in human leukemic cells is 
very unlikely, as a functional relationship between PKC level and effect of ET-18-OCH3 on PKC 
activity in different sensitive and resistant cell types could not be found [291]. Also, ET-18-
OCH3 has been reported to inhibit in a similar way PKC activity in both ET-18-OCH3-resistant 
K562 and sensitive HL-60 cells [290], inhibition of PKC by ether lipids was not correlated with 
their antineoplastic activity on WEHI-3B and R6X-B15 cells [292], and cells depleted of PKC 
activity showed similar sensitivity or resistance to ET-18-OCH3 as cells expressing PKC activity 
[291]. Thus, inhibition of PKC by ET-18-OCH3 does not correlate with the antitumor effect of 
the ether lipid. However, under incubation conditions where ET-18-OCH3 inhibited the 
proliferation of human breast adenocarcinoma MCF-7 cells, the ether lipid inhibited the 
phosphorylation of endogenous cellular proteins by PKC in intact cells [293]. Pretreatment of 
MCF-7 cells with ET-18-OCH3, at concentrations that inhibit cell proliferation in these cells, 
abolished the PKC-dependent phosphorylation of endogenous proteins, induced by phorbol-12-
myristate-13-acetate (PMA), in the same way as the specific PKC inhibitor Ro 31-8220, but the 
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ether lipid did not affect translocation from cytosol to membrane of α, γ and ε species of PKC 
[293]. ET-18-OCH3 has also been reported to inhibit PMA-induced protein phosphorylation in 
intact HL-60 cells [294] and in Madin Darby canine kidney (MDCK) cells [295]. Interestingly, 
ET-18-OCH3 itself stimulated the enhanced incorporation of 32P into a number of proteins, 
revealed by two-dimensional gel electrophoresis as a series of spots with a molecular weight of 
about 31 kDa, in MCF-7 cells [293]. In contrast, no effect on basal phosphorylation was 
observed in similar studies with HL-60 or K562 leukemic cell lines [294]. The intriguing 
enhanced phosphorylation in MCF-7 cells could be due to inhibition of phosphatases or 
activation of kinases by ET-18-OCH3, and its relevance in ET-18-OCH3-mediated actions in 
MCF-7 cells, if any, remains to be elucidated. ET-18-OCH3 did not enhance protein kinase A 
activity [260]. In addition, some reports indicate that ET-18-OCH3 antagonizes a number of 
additional biochemical effects of PKC stimulation by PMA, including transcription [295,296]. 
PMA and cell permeable diacylglycerol analogues (DiC8) inhibit the induction of apoptosis by 
the anti-neoplastic agent cytosine arabinoside (ara-C; 1-β-D-arabinofuranosylcytosine) [297], a 
DNA synthesis inhibitor that has been shown the most effective single agent against acute 
myelogenous leukemia [298], whereas down-regulation of PKC with bryostatin I results in 
enhanced apoptosis by ara-C in HL-60 cells [299]. In these cells, ara-C-induced apoptosis was 
stimulated by pretreatment with ET-18-OCH3 [300], which inhibits both ara-C and PMA-
induced translocation of PKCβII [300]. 
Also, ET-18-OCH3 inhibits PMA-stimulated PLD activity and DNA synthesis in NIH 
3T3 fibroblasts [301], suggesting an inhibitory effect of ET-18-OCH3 on PKC. Another piece of 
indirect evidence for the inhibitory effect of the ether lipid on PKC has been provided by the 
observation that ET-18-OCH3 inhibits PMA-induced activation of NF-κB, but not that induced 
by TNFα or IL-1α [302]. 
Quaternary ammonium analogues of ET-18-OCH3 have been reported to show PKC 
inhibitory activity in a cell-free system assay by acting as competitive inhibitors of activation by 
phosphatidylserine [303], and to inhibit the activation of PKC in intact cells and the growth of 
human leukemia cell lines [304]. In a more recent study, ET-18-OCH3 incorporated into 
liposomes, composed of dioleoylphosphatidylcholine:cholesterol: 
dioleoylphosphatidylethanolamine-glutaric:ET-18-OCH3 (4:3:1:2, v/v), known as ELL-12 [305], 
had no significant effect on PKC activity or translocation induced by PMA in NIH 3T3 
fibroblasts and in human leukemic Jurkat T cells [306]. Furthermore, ELL-12 did not inhibit 
PMA-induced translocation of cPKCα and nPKCδ to the membrane and did not affect the 
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cellular distribution of the atypical PMA-insensitive PKCζ [306]. Also, ELL-12 did not induce 
down-regulation of cPKCα, nPKCδ, or PKCζ [306]. 
 These contradictory results indicate that experiments on inhibition or activation of PKC 
by ET-18-OCH3 have to be interpreted with caution since different results can be obtained 
depending on the cell examined as well as on the experimental procedure followed to assay PKC 
activity and the way of presentation of ET-18-OCH3. Also, the possibility of a non-specific 
detergent effect of ET-18-OCH3 cannot be excluded, as many of the reported effects of ET-18-
OCH3 on PKC activity have been obtained when used at very high doses. At any case, the fact 
that similar effects on PKC activity have been reported on both ether lipid-resistant and sensitive 
cells, and the lack of a functional relationship, in many of the cases examined, between the 
actions promoted by ET-18-OCH3 on PKC activity with respect to its cytotoxic capacity, 
suggests that the antitumor effect of ET-18-OCH3 must result from actions on other intracellular 
targets. Although a definitive answer on the effect of ET-18-OCH3 on PKC remains to be 
established, especially taking into consideration all the distinct PKC isoforms, a possible role for 
PKC in ET-18-OCH3-mediated cytotoxicity, however, seems highly questionable. 
 
10. Preclinical studies 
10.1.Toxicity 
ATLs show little systemic toxicity in mice and rats regardless of the route of 
administration [1,4,187,307]. Mice injected daily for three weeks with ET-18-OCH3 at doses 
ranging from 1 µg/mouse (≈ 0.05 mg/kg of body weight) to 100 µg/mouse (≈ 5 mg/kg) when 
ET-18-OCH3 was dissolved in PBS, and up to 500 µg/mouse (≈ 25 mg/kg) when ET-18-OCH3 
was bound to serum proteins, did not show any pathologic values in blood and urine, irrespective 
of the application route, and pregnancies, births and the newborns showed no deviations from 
normal and developed without phenotypic abnormalities [1]. In both rats and mice single doses 
below 40 mg/kg of body weight are well tolerated. The oral LD50 dose for ET-18-OCH3 in both 
mice and rats is 250 mg/kg of body weight, and the main toxic effect was gastrointestinal 
irritation [1,2,4]. Death in mice follows an extreme drop of body temperature. When ET-18-
OCH3 is given intravenously (i.v.), the major dose-limiting toxicity is hemolysis, likely due to 
the detergent nature of the agents. In acute toxicity studies, the LD50 values for single-dose i.v. 
administration of ET-18-OCH3 in mice, rats, and guinea pigs are reported to be between 40 and 
55 mg/kg [2,308]. Irritation was observed at the sites of intravenous, intraperitoneal or 
intratumoral injection. LD50 can be higher when ET-18-OCH3 is bound to serum proteins and 
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herewith hemolysis can be reduced. There is a moderate increase in bilirubin and urea in blood. 
In studies with baboons and vervets [1,308], i.v. administration of 60 mg/kg ET-18-OCH3 killed 
50% of the animals and led to hemolysis in the surviving animals, increase in urea up to 200 mg 
%, and two baboons had enlarged kidneys on post mortem examination [308]. Other major 
organs like liver, stomach, thymus, spleen, appeared macroscopically normal. In subacute 
toxicity studies three vervets/group were injected three times/week with 1 mg/kg, 5 mg/kg and 
20 mg/kg for 3 weeks. No side effects or pathologic values in blood and urine were found 
[1,308]. Higher doses led to diarrhea, vomiting and hemolysis with transient increase of bilirubin 
and urea in blood, and accompanied by an increase of hemoglobin, protein and glucose in urine 
[1, 308]. The LD50 in rabbits was 5 mg/kg given i.v. in saline. The reason for this extraordinarily 
low LD50 is unknown, but this i.v. LD50 can further be raised up to 100 mg/kg when given slowly 
within 1-2 h, dissolved in serum or 5% albumin. 
Significantly, the ET-18-OCH3 did not induce any myelotoxicity or bone marrow toxicity 
in vivo, which is so often characteristic of the conventional DNA-directed anticancer agents. In 
general, ET-18-OCH3 treatment does not result in significant systemic side effects and are 
tolerated well in animal models, and these findings have been confirmed in the later clinical 
trials. On the other hand, no mutagenic [309] or cytogenetic [310] effects were detected upon 
ET-18-OCH3 treatment. 
In cultured rat hepatocytes incubated with different concentrations of ET-18-OCH3 for 24 
h, the LC50 (drug concentration causing 50% of cell death) was very high 170 µM, as measured 
by lactate dehydrogenase release [124], indicating that this drug does not show hepatotoxicity. 
 
10.2. Pharmacokinetics 
A major problem in pharmacokinetic studies is the lack of a reliable method for 
quantifying non-radiolabeled ET-18-OCH3 in plasma and other organs, because of the excess of 
endogenous phospholipids present in plasma and the difficulty of detecting AEPs in low 
concentrations. However, a number of chromatographic methods to determine lysophospholipids 
and analogues are being developed [311-317], and hopefully can be used in near future to allow 
more accurate AEP determinations in animal tissues. 
Synthetic antitumor ether lipids, including ET-18-OCH3, considered in a broad sense as 
analogues of LPC, have a markedly higher metabolic stability in vivo than the natural compound. 
Pharmacokinetic data reveal gastrointestinal absorption of ET-18-OCH3 after oral administration 
[311]. Furthermore, ATLs are slowly degraded in vivo, resulting in half-lives in the order of days 
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[139,318]. This stability, together with the accumulation of ET-18-OCH3 in the gastrointestinal 
tract, permits the absorption of the undegraded ET-18-OCH3 from the intestinal tract and, hence, 
oral application. 
Using NMRI mice, Arnold and co-workers [139] found that, shortly after (60 min) 
intravenous injection of radiolabeled ET-18-OCH3, this ether lipid was distributed throughout 
the animal, and this distribution did not change between 1 and 10 h after injection. After 5 h of 
intravenous injection, the intestinal tract accumulated about 16-20% of the total activity 
recovered per organ, liver accumulated 12-14%, kidneys accounted for about 5-7%, blood for 2-
6%, lungs for 2-3%, and the other organs examined (stomach, spleen, thymus, heart, and brain) 
accumulated about 1% [139]. In most of the organs, a large amount of the accumulated activity 
remained undegraded (less than 40% degradation) after 4 days following ET-18-OCH3 injection, 
and even in liver degradation resulted only in about 60% [139]. ET-18-OCH3 dispersal in the 
body was similarly achieved irrespective of the administration route used, namely intravenous, 
intraperitoneally, oral and subcutaneous. However, these latter two dosing routes resulted in 
slower distribution throughout the entire animal and in significant depot effects in the gastro-
intestinal tract and skin, respectively [139]. Experiments with tumor-bearing mice indicated that 
ET-18-OCH3 accumulated in the tumor, without undergoing degradation for long periods of 
time, with a relatively high tumor/healthy tissue ratio [139]. This might explain the relative 
enrichment of these compounds in the tumor in vivo. In this regard, a 125I-containing analogue of 
ET-18-OCH3 was accumulated into tumor tissue with time and reached a tumor/blood ratio of 
30:1 in a human colon carcinoma and 8:1 in a human melanoma xenograft in mice, proving to be 
useful for γ-scintigraphic tumor visualization [319]. Also, radioiodinated AEP and APC 
analogues have been shown to be selectively retained by a variety of rodent and human tumors 
[319-322], suggesting a potential role for these radiopharmaceutical ATL analogues as tumor 
imaging agents. 
Surprisingly, a study of ET-18-OCH3 in rats, where the ether lipid was determined by 
high-performance thin-layer chromatography, reported that intact ET-18-OCH3 could not be 
detected in urine and feces, and did not accumulate significantly in tissues, suggesting a high 
level of biotransformation [138]. This is in total contrast with the pharmacokinetic data from 
mice. This discrepancy could be due to technical problems in detecting ET-18-OCH3 levels or to 
great differences found in the metabolism of ET-18-OCH3 between animal species. 
 
10.3. Assays in animal models 
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In parallel to studies in vitro, the antitumor effect of ET-18-OCH3 has been studied in 
different tumor models in animals. ET-18-OCH3 retarded the growth of Ehrlich ascites tumor 
cells or Meth-A sarcoma cells in vivo  [2]. ET-18-OCH3 showed moderate effects, after oral 
administration, on the subcutaneously (s.c.) transplantable mammary tumors TMA1 and TMA2 
in BD-VI rats [323]. Oral administration of 10 mg/kg ET-18-OCH3 twice daily inhibited 
partially the growth of methylnitrosourea-induced mammary carcinomas in Sprague-Dawley rats 
[324]. This treatment was well tolerated without symptoms of toxicity. Oral administration of 6 
mg/kg ET-18-OCH3 did not exert any significant tumor-inhibiting effect, and administration of 
60 mg/kg ET-18-OCH3 caused stagnation in tumor growth, but clear toxic effects were observed, 
as manifested by a 13% weight loss in 3 weeks and a 30% mortality [324]. This could indicate a 
narrow therapeutic index of ET-18-OCH3 in single-drug therapy, and therefore it can be 
suggested that the putative use of this compound in combination with other drugs might improve 
the therapeutic index of the ether lipid. ET-18-OCH3 administration significantly protected 
against leukemia development in 7,12-dimethylbenzanthracene-treated Long Evans rats [325]. 
However, the ether lipid had no effect in acetoxymethyl methylnitrosamine-induced rat colonic 
adenocarcinomas [326, 327]. In general, the responses obtained with different animal model 
studies have been moderate. However, the results were improved when ET-18-OCH3 was given 
together with low doses of classical chemotherapeutic compounds, such as cis-platinum, 
cyclophosphamide and vinca-alkaloids [2]. 
In vivo antitumor activity of ET-18-OCH3 against human solid tumors has also been 
shown using congenitally athymic mutant nude mice. Twenty two different human gynecologic 
malignant primary tumor cells (11 ovarian carcinoma, 8 endometrial carcinoma, 1 cervix 
carcinoma, 1 teratoblastoma, 1 ovarian tube carcinoma), that were shown to be killed in vitro 
following treatment with ET-18-OCH3, were transplanted subcutaneously in NMRI nude mice 
and ET-18-OCH3 was found to induce a significant retardation of the in vivo growing human 
tumors [327]. The ether lipid was administered daily either i.v. through the tail vein (500 µg ET-
18-OCH3 dissolved in NMRI mouse serum/mouse/day), or given orally (500 µg ET-18-OCH3 
dissolved in PBS/mouse/day), and no apparent side effects were recognized during the 3-week 
period of treatment [327]. The growth of MEXF 274 melanoma in NMRI nude mice was slightly 
retarded by intraperitoneal (i.p.) administration of 10 or 30 mg/kg body weight of ET-18-OCH3, 
and the growth of the lung adenocarcinoma LXFA 526 was very weakly retarded after i.p. 
administration of 30 mg/kg body weight of ET-18-OCH3 [328]. Intraperitoneal administration of 
ET-18-OCH3 did not increase the survival time of nude mice inoculated with L1210 murine 
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leukemia cells [328]. On the other hand, ET-18-OCH3 (10 mg of ether lipid dissolved in 0.9% 
sodium chloride/kg body weight, injected s.c. on the left rear flank three times per week for 2 
weeks) reduced tumor growth of the MDA-MB 231 human breast carcinoma cell line injected 
s.c. in athymic nude Harlan Sprague Dawley mice consuming a fish oil diet [329]. Again there 
were no detectable harmful side effects on mice following ET-18-OCH3 treatment [329]. Human 
glioma xenografts in NMRI nude mice were reported to be sensitive to intratumorally applied 
ET-18-OCH3 [330]. 
In conclusion, a great variability has been found in the responses to ET-18-OCH3 with 
tumors treated identically with nude mice bearing human tumors. Taken together, the in vivo 
experiments carried out to examine the antitumor capacity of ET-18-OCH3 showed a rather poor 
antitumor effect of ET-18-OCH3 in single-drug therapy. In general, although some limited 
antitumor activity has been reported in vivo, no convincing potent antitumor effect has been 
observed in animal models. Also the different results reported with different tumors seem to 
suggest a rather tumor-specific action of ET-18-OCH3. 
 
11. Clinical studies 
 ET-18-OCH3 shows low toxicity and is a non-myelosuppressive agent. So far, purging in 
autologous bone marrow transplantation is the major indication for a putative clinical use of ET-
18-OCH3. 
 
11.1. Phase I studies 
In the period 1979-1982, sixteen patients suffering from advanced solid tumors or 
leukemias, with metastatic or widespread disease, and found in poor general health (Karnofsky 
performance score below 50 in most of the patients), the majority (fourteen) refractory to prior 
treatment, were treated in a phase I pilot study with ET-18-OCH3 [331-333]. Eleven patients 
were treated intravenously, and five were given oral therapy. ET-18-OCH3 was aseptically 
dissolved in 20% human albumin and infused i.v. Prolonged i.v. administration of 15-20 mg ET-
18-OCH3/kg/day at a concentration of 5 mg/ml ET-18-OCH3 containing 20% human serum 
albumin could be continued safely. The maximum tolerated dose for the i.v. treated patients was 
either 50 mg/kg as a single injection, with limited toxicity in the gastrointestinal tract, with 
vomiting and diarrhea, or 20 mg/kg during daily dispensions, with reversible interstitial 
pulmonary edema and impairment of hepatic function as dose-limiting toxicity. Mitogen 
stimulation and mixed lymphocyte culture studies revealed possible immunosuppressive effects 
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of high doses of ET-18-OCH3. Intravenous and oral treatment showed few encouraging response 
data since there were two partial remissions (defined as regression of all tumor parameters of 
more than 50% with a remission duration for at least one month) in non-small cell lung (NSCL) 
cancers with remission durations of 5 and 6 months, and a reduction of peripheral leukemic 
blasts to less than 10% in an acute myelomonocytic leukemia [331-333]. There were no 
chromosomal changes in cytogenetic studies [310]. Frequent post-mortem examinations revealed 
no further toxicity. 
Importantly, hematological or systemic side effects such as myelosuppression, nephro-, 
neuro- or hepatotoxicity were rarely observed in the clinical studies with ET-18-OCH3, even 
after prolonged therapy, and this feature distinguishes this antitumor agent from the anticancer 
agents currently available in the clinic. 
 
11.2.Phase II studies 
The evaluation of a phase II study with 116 NSCL patients treated with ET-18-OCH3 has 
been rather disappointing [334]. ET-18-OCH3 was initially applied in a daily oral dosage of 300 
mg (dissolved in milk) over a period of 4 weeks, and then increased to a daily dosage of 900 mg 
if tolerated well. Eighty one patients could be evaluated for remission status, but only 2 of them 
showed a partial remission, 68 showed no change, and 11 had unaltered progression of the 
tumor. 
 Interestingly, ET-18-OCH3 has been reported to reduce circulating blasts in a patient with 
acute myelomonocytic leukemia refractory to treatment with daunomycin, cytosin arabinoside 
and thioguanine [332]. In May 1981 the patient entered a phase I study with ET-18-OCH3 in a 
very poor general condition (Karnofsky index, 20; 84600 white blood cells/µl with 93% of 
leukemic cells) and received intravenously ET-18-OCH3 dissolved in human albumin, at 
different doses ranging between 16-30 mg ET-18-OCH3/kg/day. After 11 days of daily 
treatment, the white blood count was 27800 leukocytes/µl with 64% of leukemic cells and 
recovery of normal hematopoiesis was first observed in the peripheral blood with an increase of 
neutrophils. Normal white blood count (6600 leukocytes/µl) was reached at day 15, but leukemic 
cells were still 51%. Then, after one-month period without ether lipid treatment due to septic 
temperatures developed by the patient 3 days after hospital admission, white blood count again 
increased to 24400 leukocytes/µl with 84% of leukemic cells. When ET-18-OCH3 application 
was resumed a second drop in the white blood count was observed though to a lesser extension, 
reaching a leukocyte count of 18000 with a leukemic population of 62%. Despite normal 
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hematopoiesis began to recover, the patient again developed septic temperatures dying on July 
15th, 1981 [332]. 
 
12. Purging 
Leukemic cells are particularly sensitive to the cytotoxic action of ET-18-OCH3, whereas 
normal bone marrow cells are relatively spared [11,37,335-338]. Normal bone marrow 
progenitor cells were not inhibited at drug doses that eliminated clonogenic leukemic cells in a 
mixture of normal and leukemic cells [339,340]. In a myelomonocytic mouse model, where a 
mixture of normal bone marrow and WEHI/3b leukemic cells were exposed to the ether lipid for 
24 h before injection into lethally irradiated Balb/c littermates, there was a dose-related increase 
in survivors among the treated group, whereas the untreated animals succumbed to leukemia 
[341,342]. On these grounds ET-18-OCH3 was considered to be a good candidate for purging 
remission marrows before autologous bone marrow transplantation in leukemic patients, as it 
could be safely used for purging without prolonging marrow recovery due to its selectivity. In 
the autologous transplant setting, contamination of the graft by residual tumor cells is a risk for 
relapse after high-dose tumor therapy [343-346], and removal of tumor cells from bone marrow 
grafts by chemopurging with the selective antitumor agent ET-18-OCH3 seemed to be an 
effective and simple method. Purging in autologous bone marrow transplantation in leukemic 
patients has become so far the major indication for a putative clinical application of ET-18-
OCH3, and the groups of Wolfgang E. Berdel in Berlin (Germany) and William R. Vogler in 
Atlanta (USA) have carried out a lot of effort in this address. However, results, though 
encouraging, have not matched expectations. In these preclinical and clinical assays, the effect of 
cryopreservation was also analyzed since autologous marrow grafts are cryopreserved prior to 
reinfusion into the patient, and therefore the data including cryopreservation are obviously most 
relevant for potential clinical applications. 
When the dose of ET-18-OCH3 was increased and the incubation time shortened to 4 h 
the majority of leukemic cells were killed with very little effect on normal marrow progenitor 
cells [347]. This selective cytotoxicity prompted the use of ET-18-OCH3 in purging marrow 
from leukemic patients in remission in preparation for autologous bone marrow transplantation. 
From April 1988 to February 1992 twenty nine patients with acute leukemia (19 acute 
myelogenous leukemia –AML- patients and 10 acute lymphoblastic leukemia –ALL- patients) 
entered into a clinical trial to assess the usefulness of ET-18-OCH3 in purging marrow from 
leukemic patients in preparation for autologous bone marrow transplantation [348-350]. 
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Leukemic patients received marrow-ablative chemotherapy and total body irradiation followed 
by infusion of marrow purged for 4 hours at 37ºC with ET-18-OCH3. The cell concentration was 
adjusted to 2 x 107 cells/ml with RPMI 1640 medium and 10% autologous plasma and the initial 
purging dose of ET-18-OCH3 was 50 µg/ml. Then, the purging dose was increased to 75 µg/ml, 
and this concentration became the recommended one for purging. One patient whose marrow 
was purged with 100 µg/ml failed to engraft. These studies led to the conclusion that 
cryopreservation in concert with purging with 75 µg/ml ET-18-OCH3 represented a novel 
treatment in purging with encouraging results.  In contrast to purging with cyclophosphamide 
derivatives in which normal bone marrow progenitor cells are markedly reduced [351-353], ET-
18-OCH3 had no effect on these cells when used either at 50 or 75 µg/ml doses before or after 
freezing. However, cryopreservation significantly reduced the number of normal bone marrow 
progenitor cells by about 35%, but this reduction was not augmented by ET-18-OCH3 exposure. 
Following transplantation, the median time to granulocyte recovery to ≥500/µl was 26 and 38 
days for the 50 and 75 µg/ml ET-18-OCH3 doses, respectively; and the median time to platelet 
recovery to ≥25000/µl was 43 and 49 days for the 50 and 75 µg/ml doses, respectively. These 
recovery times were in the absence of G-CSF. One patient that was given granulocyte-colony 
stimulating factor (G-CSF) had recovery of granulocytes to ≥500/µl by day 10 and to ≥1000/µl 
by day 12. The Kaplan-Meier plots of survival and disease-free survival of the 29 patients 
indicated that nine patients (31%) remained in remission free of leukemia for a median of 630 
days from 185 to 1613 days. 
 As hematologic recovery time after high-dose tumor therapy is greatly reduced by the use 
of peripheral blood derived progenitor cells (PBPC) when compared to bone marrow derived 
grafts [354,355], a study was accomplished to examine the effect of ET-18-OCH3 in the 
hematological recovery time from purged leukapheresis [356]. Buffy coats from peripheral blood 
of patients with breast cancer, non-Hodgkin’s lymphoma multiple myeloma and primitive 
neuroectodermal tumor (PNET), were resuspended at 2 x 107 cells/ml in RPMI 1640 containing 
10% autologous plasma and treated with 75 µg/ml ET-18-OCH3 for 4 h at 37ºC. Then, cells were 
frozen and stored in liquid nitrogen until use. The fraction of CFU-GM out of all CD34+ cells 
ranged between 1-10% (6.3 ± 1.6%) in these leukapheresis. The recovery of total progenitor cells 
(total CFU including myeloid –cluster, CFU-GM-; erythroid -BFU-E, CFU-E-; and mixed -CFU-
GEMM-), quantified in semisolid cultures, was about 71% after purging, 63% after 
cryopreservation only, and about 47% after purging and cryopreservation; and the recovery of 
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CFU-GM was 80% after purging, 63% after cryopreservation only, and 48% after purging and 
cryopreservation. When comparable numbers of CFU-GM were used for transplantation after 
high-dose therapy, the clinical recovery times for leukocytes and platelets remained unchanged 
in comparison to patients receiving non-purged PBPC. White blood cell counts dropped to <100 
white blood cells/µl and to <20000 platelets/µl following high-dose therapy and recovery after 
autologous PBPC transplantation was supported by 10 µg/kg/day s.c. G-CSF in all patients. The 
median recovery times of non-purged vs. purged grafts to >500 white blood cell/µl were 9 vs. 8.5 
days after transplantation, to > 2000 granulocytes/µl 10.5 vs. 10 days, and to >50000 platelets/µl 
15.5 vs. 14 days, indicating a slight tendency towards shorter recovery times in patients receiving 
purged grafts. This suggests that ET-18-OCH3 purging of PBPC and cryopreservation leads to a 
significant, but tolerable loss of progenitor cells, with a rather short hematological recovery, 
indicating that the remaining progenitors after ether lipid treatment and cryopreservation are not 
qualitatively damaged and thereby this treatment does not compromise the advantage of rapid 
hematological recovery times with PBPC. However, the above reports placed particular 
emphasis on the effect of the ether lipid on normal progenitor cells and recovery times, but the 
action of the ether lipid on eliminating leukemic cells was not appropriately analyzed.  
As mentioned above, a major limitation of autologous bone marrow transplantation is the 
putative contamination of the bone marrow to be reinfused following ablative chemotherapy 
with residual occult tumor cells that cause or contribute to relapses. The major goal in purging is 
to rid the stored marrow of any residual tumor cell and some approaches are being considered to 
increase the efficacy of the purging activity of ET-18-OCH3 while limiting toxic effects to 
normal hematopietic stem cells in order to shorten recovery times. These two variables, killing 
tumor cells while sparing normal ones, should be carefully examined using highly sensitive 
techniques in order to set up a promising purging protocol. Different approaches are being tested 
in vitro to optimize purging conditions. One approach to augment ether lipid purging activity is 
to use two (or more) synergistically interacting purging agents in combination. In this regard, 
Yamazaki and Sieber [357] have reported that ET-18-OCH3 synergistically enhances in vitro the 
antileukemic effect of merocyanine 540 (MC540)-mediated photodynamic therapy (PDT). A 
potent synergistic effect was found when different human and murine leukemic cell lines (1-5 x 
106 leukemic cells/ml) were treated with MC540-mediated PDT followed by ET-18-OCH3 
incubation (50 µg/ml ET-18-OCH3 for 1 h at 37ºC, in culture medium containing 10% FCS), 
whereas the survival of normal human granulocyte-macrophage progenitors from volunteer 
donors was minimally reduced. Cryopreservation dramatically enhanced (≥3 log) the 
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antileukemic effect of purging with MC540 + ET-18-OCH3, but only moderately reduced the 
surviving fraction of CFU-GM, giving a most favorable therapeutic index when cells were 
exposed sequentially to MC540-mediated PDT, ET-18-OCH3, and cryopreservation [357]. 
The above mentioned reports used a very high dose of ET-18-OCH3, and this can be the 
reason for a partial toxic effect on normal progenitor cells. Another approach to optimize purging 
conditions in autologous bone marrow transplantation is to decrease ether lipid concentrations by 
lowering the amount of serum in the cultures. The cytotoxic effect of ET-18-OCH3 is affected by 
the proportion of serum in the culture medium [358,Gajate, C. and Mollinedo, F., unpublished 
data), decreasing the antitumor efficacy of the ether lipid with increasing concentrations of 
serum. Heesbeen and co-workers [98] have reported that the cytotoxic action and uptake of ET-
18-OCH3 was increased significantly at reduced serum levels, and that BSA was a major serum 
factor influencing ether lipid cytotoxicity. Assuming a BSA content of 23 g/l FCS, they found 
that equivalent BSA representing 2% FCS (that is 0.46 mg BSA/ml) allowed in vitro to decrease 
the amount of ether lipid to 20 µg/ml (4 h at 37ºC; 2 x 106 cells) in order to eliminate practically 
the peripheral blood leukemic cells derived from five acute myeloid leukemia patients, with a 
60% reduction in normal human bone marrow CFU-GM. Under these experimental conditions 
the use of 50 µg/ml ET-18-OCH3 led to complete destruction of normal marrow progenitors. 
These data suggest that free ET-18-OCH3 molecules are more cytotoxic than the ether lipid-
albumin complex. PAF is known to bind to albumin at four binding sites [359], and as the 
chemical structure of ET-18-OCH3 is closely related to PAF, it can be assumed that ET-18-
OCH3 shows a similar stoichiometry towards albumin. Moreover, plasma albumin has been 
found to bind fatty acids in a 4:1 ratio [360]. 
Another way to increase the efficacy of ET-18-OCH3 is through its combination with 
heat. Hyperthermia has been reported to inhibit the proliferation of leukemic cells that are more 
sensitive to hyperthermic killing than their normal counterparts [361,362]. Okamoto and co-
workers [340] combined hyperthermia and ether lipids and found that a 4-h incubation of 
leukemic cells with 50 µg/ml of ET-18-OCH3 with heat (42ºC) added during the last hour 
resulted in a further reduction of leukemic cell lines or leukemic progenitors obtained from acute 
myeloid leukemia (AML) patients, while spared 50% of normal hematopoietic progenitors after 
cryopreservation. 
 On the other hand high-dose chemotherapy with autologous bone marrow transplantation 
is a promising approach to the treatment of advanced metastatic and hormone-unresponsive 
breast cancer [363]. Dietzfelbinger and co-workers [364] treated a mixture of normal human 
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bone marrow cells with malignant HTB 19 breast cancer cells at a ratio of 100:1, to simulate an 
autologous bone marrow transplantation situation, with 75 µg/ml ET-18-OCH3 for 4 h at 37ºC 
and subsequent cryopreservation, and found a considerable reduction of HBT 19 colonies (by up 
to 1 log growth reduction), whereas the normal human hematopoietic progenitors showed a 
recovery of more than 50%. Although the purging effect of ET-18-OCH3 was less pronounced in 
breast cancer cells than in leukemic and lymphoma cells, this effect suggests that ET-18-OCH3 
could be useful for purging bone marrow for autologous bone marrow transplantation not only in 
acute leukemia, but also in other cancers, like breast cancer. 
  
13. Liposomes and ET-18-OCH3 
Despite ET-18-OCH3 shows itself as a very effective and promising antitumor agent, 
optimal clinical therapeutic exploitation of ET-18-OCH3 has been hampered in part by some side 
effects, including gastrointestinal (abdominal pain, nausea, vomiting, and diarrhea), lung, liver, 
renal, and hemolytic toxicities [3,4,333,365]. Especially hemolysis has been considered a major 
side effect of ET-18-OCH3 when applied i.v. To alleviate these adverse effects and to improve 
antitumor activity, a number of analogues of ET-18-OCH3 have been synthesized, but none has 
been shown to be clinically superior to ET-18-OCH3 thus far. In agreement with the notion that 
incorporation of anticancer drugs into liposomes usually improve therapeutic efficiency while 
markedly reduce nonspecific toxicity in vivo [366-370], a stable liposome-based formulation of 
ET-18-OCH3, named ELL-12 
(dioleoylphosphatidylcholine/cholesterol/dioleoylphosphatidylethanolamine-glutaric acid/ET-18-
OCH3) (4:3:1:2, molar ratio) has been shown to be acutely less hemolytic both in vitro and in 
vivo [149, 305, 371]. Association of ET-18-OCH3 with stable liposomes greatly reduced 
hemolytic effects –up to 20 or more times- of the free ether lipid [149,305,371,372,Mollinedo, 
F., del Canto-Jañez, E. and Gajate, C., unpublished data], suggesting that liposome association 
reduced drastically the detergent-like effect of free ET-18-OCH3, protecting cells against acute 
membrane lytic effects, while preserved the growth inhibitory [149] and apoptotic [373, 
Mollinedo, F., del Canto-Jañez, E. and Gajate, C., unpublished data] properties of the ether lipid. 
These data clearly indicate that the lytic effects are not responsible for the more specific growth-
inhibitory and apoptotic effects of ET-18-OCH3. 
In addition, the liposome formulation of ET-18-OCH3 ELL-12 was about 4-8 fold less 
acutely toxic than free ET-18-OCH3 after i.v. administration and showed a higher antitumor 
activity in vivo than ET-18-OCH3 in three tumor models, namely i.p. P388 leukemia, Lewis lung 
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cancer lung metastases and B16/F10 melanoma in mice, resulting in a therapeutic index at least 
4-fold higher than ET-18-OCH3 [371]. 
As mentioned above, an important in vivo toxicity of ET-18-OCH3 is hemolysis. Free ET-
18-OCH3 caused severe acute hemolysis in mice (approximately 5% of circulating red blood 
cells hemolysed in 30 min) at a single i.v. dose of 50 mg/kg [371] and caused detectable 
hemolysis at 12.5 mg/kg. In a comparative study of acute toxicity in C57 female mice, the 
maximum tolerated dose for i.v. administration of free ET-18-OCH3 was found to be 25-50 
mg/kg, whereas the maximum tolerated dose for ELL-12 was approximately 75-200 mg/kg 
[371]. Although the in vitro hemolytic effects of ET-18-OCH3 can be significantly reduced by 
mixing ET-18-OCH3 with albumin [374], in vivo toxicity was not significantly attenuated 
because the LD50 of a single i.v. dose of ET-18-OCH3 bound to albumin is about 50 mg/kg in 
mice [3]. It is interesting to note that the acute toxicity of free ET-18-OCH3 and ELL-12 seemed 
to be reduced in tumor-bearing animals [371]. Also, ELL-12 showed much lower detectable 
toxicity than ET-18-OCH3 by the s.c. route. 
Association with liposomes reduces the in vivo toxicities of several drugs, and most 
liposome formulations used in clinical trials have been developed to reduce parent drug toxicities 
while maintaining therapeutic efficacy [367,368,375]. However, the propensity of liposomal 
drug carriers to be taken up by the phagocytic cells of the reticuloendothelial system can affect 
many important properties, especially the in vivo circulation lifetime. Some factors that influence 
the rate of liposome clearance by phagocytic cells include serum C3 complement factor that 
opsonizes particles and liposomes [376,377], liposomal size, surface charge, surface 
hydrophilicity, specific lipid composition, and aggregation [378]. Because liposome-associated 
ET-18-OCH3 ELL-12 is able to reduce side-effects, preserving antitumor activity, developing of 
new liposome-associated ET-18-OCH3 formulations with reduced uptake by the phagocytic cells 
leading to enhanced circulation lifetimes can be an important goal to achieve a better therapeutic 
efficacy of ET-18-OCH3 when administered i.v. 
 
14. Additional therapeutic indications of ET-18-OCH3 
ET-18-OCH3 and other ATLs have also attracted scientific and clinical interest in the 
treatment of diseases other than cancer and some in vitro and in vivo studies support their 
biomedical role in these new therapeutic indications. 
 It has been reported that ET-18-OCH3 prevents induction of chronic relapsing 
experimental allergic encephalomyelitis (EAE) in rats and mice [379-382]. EAE is an 
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experimental autoimmune disease of the central nervous system white matter, characterized by a 
T-cell response to myelin basic protein, sharing clinical and pathological features with human 
multiple sclerosis, and is therefore regarded as a good experimental model for human 
demyelinating disease [383-385]. In a pilot study with a limited number of multiple sclerosis 
patients, at different stages of the disease, ET-18-OCH3 treatment (150-300 mg twice/week) 
improved their clinical symptoms [2]. Although EAE in animals and multiple sclerosis in 
humans cannot be fully compared, it has been assumed that in both diseases autoaggressive T-
lymphoblats play a key role [386]. ET-18-OCH3 has been reported to kill selectively mitogen-
activated peripheral blood lymphocytes by apoptosis in vitro, whereas resting lymphocytes are 
not affected [85,387]. These data suggest a putative beneficial role of ET-18-OCH3 in certain 
autoimmune diseases, including those involving the central nervous system. In this regard, it is 
worthwhile to note that ET-18-OCH3 is able to cross the blood brain barrier [139]. 
 ET-18-OCH3 and a number of analogues have been reported to inhibit human 
immunodeficiency virus (HIV) reverse transcriptase and the production of infectious virus 
particles [388,389], suggesting a potential role as anti-HIV agents. 
 A major biomedical activity of ATLs, in particular HPC (miltefosine) and ET-18-OCH3 
(edelfosine), seems to be as antiparasitic agents. ATLs have been reported to show in vitro and in 
vivo cytotoxic activity against a number of parasites, including Leishmania (L. donovani, L. 
major, L. mexicana, L. panamensis, L. infantum), Trypanosoma cruzi, Trypanosoma brucei and 
Entamoeba histolytica [390-399]. These data together with the disponibility of ATLs as oral 
drugs raise the possibility that ATLs may have a role as an oral treatment of several parasitic 
diseases and in the growing problem of AIDS-associated visceral leishmaniasis (kala-azar) in 
CD4 cell depleted patients [400]. In this regard, it has recently shown that HPC behaves an 
effective oral medication for Indian visceral leishmaniasis [401]. In a multicenter, phase II trial 
in which four 30-person cohorts with Indian visceral leishmaniasis received 50, 100 or 150 mg 
of HPC per day for four or six weeks, 95% of the patients were cured, defined by the absence of 
parasites in a splenic aspirate obtained two weeks after completion of treatment [401]. The 
mechanisms underlining the antiparasitic role of ATLs remain to be unraveled. Leishmania is 
known to contain high levels of ether phospholipids [402-406], and it has been suggested that a 
perturbation of the ether lipid remodeling could be responsible for the anti-leishmanial action of 
these drugs [407]. 
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Concluding remarks 
ET-18-OCH3, a synthetic analogue of LPC that is considered the prototype of AEPs and 
even of ATLs, is an interesting new class of antineoplastic agent that possesses high metabolic 
stability, localizes in cellular membranes, and has no known direct interaction with DNA. ATLs, 
including ET-18-OCH3, are distinguished by their very low rates of metabolism in vitro and in 
vivo, are active per se and not prodrugs, and they share common properties that are derived from 
their structural characteristics. ET-18-OCH3 modulates cell signalling pathways at a number of 
key stages in the signal transduction cascade, including receptor function, second messenger 
generation, and protein phosphorylation. ET-18-OCH3 shows some unique features that make 
this compound an extremely interesting antitumor drug, not only for its putative clinical use in 
cancer treatment but for its mode of action that can represent a new framework in designing 
novel antitumor drugs. The ET-18-OCH3 biological effects depend largely on the chemical 
structure of the molecule [11] and thereby, the high metabolic stability of the drug favors its 
biological action. Two major biochemical effects account for its antitumor activity, namely the 
inhibition of PC biosynthesis and the induction of apoptosis in tumor cells. ET-18-OCH3 inhibits 
certain enzymes of the phospholipid metabolism, especially CCT, involved in PC biosynthesis. 
As the normal phospholipids of cellular membranes are continuously turned over to renew the 
phospholipid moieties, the presence of non-metabolizable ET-18-OCH3 leads to an interference 
with this vital dynamic cellular process. Also, as ET-18-OCH3 is very slowly, if at all, degraded 
by tumor cells, its insertion and accumulation in the plasma membrane leads to a disarrangement 
of the phospholipid bilayer and to a drastic change in the biochemical and biophysical features of 
the plasma membrane. Also, as ET-18-OCH3 inhibits acyltransferase in the cell, while PLA2 is 
not inhibited, the continued deacylation of phospholipids can result in the accumulation of LPC 
that can contribute to the cytotoxic action of the drug. A critical process in the cytotoxic action 
of ET-18-OCH3 is due to its selective apoptotic effect for malignant cells, sparing normal cells. 
This apoptotic affect is causally related to the selective cellular uptake of the antitumor ether 
lipid drug into the cancer cell, and to the subsequent intracellular triggering of Fas/CD95, 
independently of FasL, by the ether lipid after the latter is inside the cell. Thus, ET-18-OCH3 is 
the first antitumor drug acting through the intracellular activation of the cell death receptor 
Fas/CD95. This novel mechanism of action for an antitumor drug represents a new way to target 
tumor cells in cancer chemotherapy and can be of interest as a new framework in designing 
novel antitumor drugs. Understanding how ET-18-OCH3 enters the tumor cell and triggers 
Fas/CD95 activation from inside the cell will constitute major subjects of research in the 
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following years. Unraveling these processes will open a new way to target tumor cells in cancer 
chemotherapy. The fact that ET-18-OCH3 acts through its effects on apoptotic signaling 
indicates that it can be active against a wide array of tumor cells independent of their 
proliferative capacity. This is important as many tumors have a low proliferation rate, but instead 
show a deficient apoptotic response, and thereby a high apoptotic threshold. In vivo, the 
anticancer effects of ET-18-OCH3 probably result from a combination of direct effects on the 
target cancer cells, as a major drug effect, and up-regulation of host anti-cancer defense systems, 
as a minor drug action. Interestingly, ET-18-OCH3 shows some pharmacological features of 
major importance in cancer treatment: a) selective induction of apoptosis in cancer cells, sparing 
normal cells; b) no interaction with DNA; c) lack of mutagenicity; d) it passes through the blood 
brain barrier; e) it is fully active over oral route. 
Will ET-18-OCH3 be useful in the treatment of cancer? Time will tell, since clinical trials 
have started for patients with distinct tumors. HPC, a prototype for APCs, has been recently 
marketed for the topical treatment of subcutaneous breast cancer metastases. So far, most of the 
clinical studies with ET-18-OCH3 have been incomplete or rather anecdotic, and there is a 
notorious lack of multicentric clinical trials. The fact that only some tumors respond to ET-18-
OCH3 is an indication that its overall effect is more specific than that of the classical cytostatic 
agents. Thus, before launching an exhaustive clinical study, further preclinical studies should be 
carried out in order to determine the most suitable type of cancer to be treated with ET-18-OCH3, 
to fix the optimal dose, route and way of administration, and to examine putative synergistic 
combinations with other additional drugs or therapies to increase the antitumor potential. Also, 
changes in the chemical structure of the ET-18-OCH3 leading to an increase in the antitumor 
activity of the drug, preserving its selectivity cytotoxicity against tumors and its metabolic 
stability, will be needed in order to enhance the efficiency of the drug. On the other hand, the 
selectivity of ET-18-OCH3 for cancer cells as well as its accumulation in tumors turns this drug 
into an extremely attractive compound to identify tumor localization and metastasis. 
ATLs, including ET-18-OCH3, show pleiotropic actions leading to multiple putative 
biomedical applications. Due to this pleiotropy, other therapeutic applications for these versatile 
agents may yet await discovery. Thus, ATLs are powerful drugs in the therapy of parasitic 
diseases, and are considered to be the most promising antileishmanial agents. Also, ET-18-OCH3 
seems to be an interesting drug in certain autoimmune diseases, including multiple sclerosis. 
Altogether the above data warrant further investigation to fully unravel the mechanisms of action 
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of ET-18-OCH3 in the distinct biomedical indications, and to enhance the antineoplastic effect 
and other therapeutic actions of the ether lipid.  
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LEGENDS TO FIGURES 
 
Fig. (1). Chemical structures of ET-18-OCH3 (edelfosine), platelet-activating factor (PAF) and 
hexadecylphosphocholine (HPC, miltefosine). 
 
Fig. (2). Normal and cancer cells show different “apoptosis thresholds” in response to cellular 
and genomic damage. A deficient apoptotic response in cancer cells increases their malignancy, 
favoring accumulation of mutations and rendering tumor cells resistant to therapy. 
 
Fig. (3). Response to cellular or genomic damage. Cancer cells inhibit the expression or activity 
of cellular sensors that engage apoptosis, as well as inhibit apoptotic signaling and/or enhance 
survival signaling, rendering a high “apoptosis threshold” and providing cancer cells with a high 
survival capacity in adverse conditions. 
 
Fig. (4). Metabolism of 2-lysophosphatidylcholine. 
 
Fig. (5). ET-18-OCH3-induced apoptosis and ether lipid uptake depend on the malignant state of 
the cells. 
 
Fig. (6). Metabolic pathways of ET-18-OCH3. GEMO, glyceryl-ether monooxygenase. PLA2, 
phospholipase A2. PLC, phospholipase C. PLD, phospholipase D. 
 
Fig. (7). Antitumor effects of ET-18-OCH3. 
 
Fig. (8). Hypothetical model for the proapoptoitc effect of ET-18-OCH3 in tumor cells. First, ET-
18-OCH3 is taken up selectively by tumor cells, but not by normal cells, through its interaction 
with a still unknown cell surface structure (denoted as “?”), and then the ether lipid induces the 
intracellular activation of Fas/CD95. This second step is non-selective and involves Fas/CD95 
capping and activation, JNK, mitochondria, caspase-3 and internucleosomal DNA degradation. 
Modified from [12]. 
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Fig. (9). Interaction of ET-18-OCH3 with different cellular regulatory and signaling events in 
relation to its cytotoxic activity. CK, choline kinase. CPT, choline phosphotransferase. DAG, 
diacylglycerol. 
